RECOMBINANT PROTEINS OF A PAKISTANI STRAIN OF HEPATITIS E AND THEIR USE IN DIAGNOSTIC METHODS AND VACCINES

Abstract: A strain of hepatitis E virus from Pakistan (SAR-55) implicated in an epidemic of enterically transmitted non-A, non-B hepatitis, now called hepatitis E, is disclosed. The invention relates to the expression of the whole structural region of SAR-55, designated open reading frame 2 (ORF-2), in a eukaryotic expression system. The expressed protein is capable of forming HEV virus-like particles which can serve as an antigen in diagnostic immunoassays and as an immunogen or vaccine to protect against infection by hepatitis E.

Description: o Title of the Invention RECOMBINANT PROTEINS OF A PAKISTANI STRAIN OF HEPATITIS E AND THEIR USE IN DIAGNOSTIC METHODS AND VACCINES 5 Field Of Invention The invention is in the field of hepatitis virology. More specifically, this invention relates to recombinant proteins derived from an enterically transmitted strain of hepatitis E from Pakistan, SAR-55, and to diagnostic ^Q methods and vaccine applications which employ these proteins. Background of Invention Epidemics of hepatitis E, an enterically transmitted non-A/non-B hepatitis, have been reported in Asia, Africa ^5 and Central America (Balayan, M.S. (1987), Soviet Medical Reviews, Section E, Virology Reviews, Zhdanov, V.M. (ed) , Chur, Switzerland: Harwood Academic Publishers, vol. 2 , 235-261; Purcell, R.G., et al. (1988) in Zuckerman, A.J. (ed) , "Viral Hepatitis and Liver Disease", New York: Alan 2Q R. Liss, 131-137; Bradley, D.W. (1990), British Medical Bulletin. 46:442-461; Ticehurst, J.R. (1991) in Hollinger, F.B., Lemon, S.M., Margolis, H.S. (eds): "Viral Hepatitis and Liver Disease", Williams and Wilkins, Baltimore, 501- 513) . Cases of sporadic hepatitis, presumed to be 25 hepatitis E, account for up to 90% of reported hepatitis in countries where hepatitis E virus (HEV) is endemic. The need for development of a serological test for the detection of anti-HEV antibodies in the sera of infected individuals is widely recognized in the field, but the .,« very low concentration of HEV excreted from infected humans or animals made it impossible to use such HEV as the source of antigen for serological tests and although limited success was reported in propagation of HEV in cell culture (Huang, R.T. et al. (1992) , J. Gen. Virol.. ,e 73:1143-1148), cell culture is currently too inefficient to produce the amounts of antigen required for serological tests. Recently, major efforts worldwide to identify viral genomic sequences associated with hepatitis E have resulted in the cloning of the genomes of a limited number of strains of HEV (Tarn, A.W. et al. (1991), Virology. 185:120-131; Tsarev, S.A. et al. (1992), Proc. Natl. Acad. Sci. USA. 89:559-563; Fry, K.E. et al. (1992), Virus Genes, 6:173-185). Analysis of the DNA sequences have led investigators to hypothesize that the HEV genome is organized into three open reading frames (ORFs) and to hypothesize that these ORFs encode intact HEV proteins. A partial DNA sequence of the genome of an HEV strain from Burma (Myanmar) is disclosed in Reyes et al., 1990, Science. 247:1335-1339. Tarn et al. , 1991, and Reyes et al., PCT Patent Application WO91/15603 published October 17, 1991 disclose the complete nucleotide sequence and a deduced amino acid sequence of the Burma strain of HEV. These authors hypothesized that three forward open reading frames (ORFs) are contained within the sequence of this strain. Ichikawa et al., 1991, Microbiol. Immunol.. 35:535- 543, discloses the isolation of a series of clones of 240- 320 nucleotides in length upon the screening of a λgtll expression library with sera from HEV-infected cynomolgus monkeys. The recombinant protein expressed by one clone was expressed in E. coli. This fusion protein is encoded by the 3' region of ORF-2 of p e Myanmar strain of HEV. The expression of additional proteins encoded within the 3 ' region of ORF-2 of a Mexican strain of HEV and of a Burmese strain of HEV is described in Yarbough et al., 1991 J. Virology. 65:5790-5797. This article describes the isolation of two cDNA clones derived from HEV. These clones encode the proteins in the 3' region of ORF-2. The clones were expressed in E. coli as fusion proteins. Purdy et al., 1992, Archives of Virology. 123:335- 349, and Favorov et al., 1992, J. of Medical Virology. 36:246-250, disclose the expression of a larger ORF-2 protein fragment from the Burma strain in E. coli. These references, as well as those previously discussed, only disclose the expression of a portion of the ORF-2 gene using bacterial expression systems. Successful expression of the full-length ORF-2 protein has not been disclosed until the present invention. Comparison of the genome organization and morpho¬ logical structure of HEV to that of other viruses revealed that HEV is most closely related to the caliciviruses. Of interest, the structural proteins of caliciviruses are encoded by the 3' portion of their genome (Neil, J.D. et al. (1991) J. Virol.. 65:5440-5447; and Carter, M.J. et al. (1992), J. Arch. Virol.. 122:223-235) and although there is no direct evidence that the 3' terminal part of the HEV genome also encodes the structural proteins, expression of certain small portions of the 3' genome region in bacterial cells resulted in production of proteins reactive with anti-HEV sera in ELISA and Western blots (Yarborough, et al., (1991); Ichikawa et al. (1991); Favorov et al. (1992) and Dawson, G.J. et al. (1992) J. Virol. Meth; 38:175-186). However, the function of ORF-2 protein as a structural protein was not proven until the present invention. The small proteins encoded by a portion of the ORF-2 gene have been used in immunoassay to detect antibodies to HEV in animal sera. The use of small bacterially expressed proteins as antigens in serological immunoassays has several potential drawbacks. First, the expression of these small proteins in bacterial cells often results in solubility problems and in non-specific cross-reactivity of patients' sera with E. coli proteins when crude E. coli lysates are used as antigens in immunoassays (Purdy et al. (1992)). Second, the use of Western blots as a first-line serological test for anti-HEV antibodies in routine epidemiology is impractical due to time and cost constraints. An ELISA using small-peptides derived from the 3'-terminal part of the HEV genome resulted in the detection of only 41% positives from known HEV-infected patients. Third, it has been shown that for many viruses, including Picornaviridae which is the closest family to the Caliciviridae, important antigenic and immunogenic epitopes are highly conformational (Lemon, S.M. et al. (1991), in Hollinger, F.B., Lemon, S.M., Margolis, H.S. (eds): "Viral Hepatitis and Liver Disease", Williams and Wilkins, Baltimore, 20-24) . For this reason, it is believed that expression in a eukaryotic system of a complete ORF encoding an intact HEV gene would result in production of a protein which could form HEV-virus-like particles. Such a complete ORF protein would have an immunological structure closer to that of native capsid protein(s) than would the above-noted smaller proteins which represent only portions of the structural proteins of HEV. Therefore, these complete ORF proteins would likely serve as a more representative antigen and a more efficient immunogen than the currently-used smaller proteins. Summary Of Invention The present invention relates to an isolated and substantially pure preparation of a human hepatitis E viral strain SAR-55. The invention also relates to an isolated and sub¬ stantially pure preparation of the genomic RNA of the human hepatitis E viral strain SAR-55. The invention further relates to the cDNA of the human hepatitis E viral strain SAR-55. It is an object of this invention to provide syn¬ thetic nucleic acid sequences capable of directing production of recombinant HEV proteins, as well as equivalent natural nucleic acid sequences. Such natural nucleic acid sequences may be isolated from a cDNA or genomic library from which the gene capable of directing synthesis of the HEV proteins may be identified and isolated. For purpose of this application, nucleic acid sequence refers to RNA, DNA, cDNA or any synthetic variant thereof which encodes for protein. The invention further relates to a method for detection of the hepatitis E virus in biological samples based on selective amplification of hepatitis E gene fragments utilizing primers derived from the SAR-55 cDNA. The invention also relates to the use of single- stranded antisense poly-or oligonucleotides derived from the SAR-55 cDNA to inhibit the expression of hepatitis E genes. The invention also relates to isolated and substan¬ tially purified HEV proteins and variants thereof encoded by the HEV genome of SAR-55 or encoded by synthetic nucleic acid sequences and in particular to recombinant proteins encoded by at least one complete open reading frame of HEV. The invention also relates to the method of preparing recombinant HEV proteins derived from an HEV genomic sequence by cloning the nucleic acid and inserting the cDNA into an expression vector and expressing the recombinant protein in a host cell. The invention also relates to the use of the resultant recombinant HEV proteins as diagnostic agents and as vaccines. The present invention also encompasses methods of detecting antibodies specific for hepatitis E virus in biological samples. Such methods are useful for diagnosis of infection and disease caused by HEV, and for monitoring the progression of such disease. Such methods are also useful for monitoring the efficacy of therapeutic agents during the course of treatment of HEV infection and disease in a mammal. This invention also relates to pharmaceutical compo- sitions for use in prevention or treatment of Hepatitis E in a mammal. Description Of Figures Figure 1 shows the recombinant vector used to express the complete ORF-2 protein of the genome of HEV strain SAR-55. Figures 2A and 2B are sodium dodecyl sulfate- polyacrylamide gels (SDS-PAGE) in which cell lysates of insect cells infected with wild-type baculovirus or recombinant baculovirus (containing the gene encoding ORF- 2) were either stained with Coomassie blue (A) or subjected to Western blotting with serum of an HEV- infected chimp (B) . Figures 3A and 3B show immunoelectron micrographs (IEM) of 30 and 20 n virus-like particles respectively, which are formed as a result of the expression of ORF-2 protein in recombinant infected insect cells. Figure 4 shows the results of an ELISA using as the antigen, recombinant ORF-2 which was expressed from insect cells containing the gene encoding the complete ORF-2. Serum anti-HEV antibody levels were determined at various times following inoculation of cynomolgus monkeys with either the Mexican (Cyno-80A82, Cyno-9A97 and Cyno 83) or Pakistani (Cyno-374) strains of HEV. Figures 5A-D show the results of an ELISA using or the antigen, recombinant ORF-2 which was expressed from insect cells containing the gene encoding the complete ORF-2. Serum IgG or IgM anti-HEV levels were determined over time following inoculation of two chimpanzees with HEV. Figures 6A-J show a comparison of ELISA data obtained using as the antigen the recombinant complete ORF-2 protein derived from SAR-55 as the antigen vs. a recombinant partial ORF-2 protein derived from the Burma strain of HEV (Genelabs) . Detailed Description of Invention The present invention relates to an isolated and substantially purified strain of hepatitis E virus (HEV) from Pakistan, SAR-55. The present invention also relates to the cloning of the viral genes encoding proteins of HEV and the expression of the recombinant proteins using an expression system. More specifically, the present invention relates to the cloning and expression of the open reading frames (ORF) of HEV derived from SAR-55. The present invention relates to isolated HEV pro- teins. Preferably, the HEV proteins of the present invention are substantially homologous to, and most preferably biologically equivalent to, the native HEV proteins. By "biologically equivalent" as used throughout the specification and claims, it is meant that the compositions are capable of forming viral-like particles and are immunogenic. The HEV proteins of the present invention may also stimulate the production of protective antibodies upon injection into a mammal that would serve to protect the mammal upon challenge with a wild type HEV. By "substantially homologous" as used throughout the ensuing specification and claims, is meant a degree of homology in the amino acid sequence to the native HEV pro¬ teins. Preferably the degree of homology is in excess of 70%, preferably in excess of 90%, with a particularly preferred group of proteins being in excess of 99% homologous with the native HEV proteins. Preferred HEV proteins are those proteins that are encoded by the ORF genes. Of particular interest are pro¬ teins encoded by the ORF-2 gene of HEV and most particularly proteins encoded by the ORF-2 gene of the SAR-55 strain of HEV. The preferred proteins of the present invention, encoded by the ORF-2 gene, form virus- like particles. The amino acid sequences of the ORF-1, ORF-2 and ORF-3 proteins are shown below as SEQ ID NO.: 1, SEQ ID NO.: 2, and SEQ ID NO. : 3, respectively: (SEQ. ID NO. : 1) Pro Ala His He Trp Asp Arg Leu Met Leu Phe Gly Ala Thr Leu 320 325 330 Asp Asp Gin Ala Phe Cys Cys Ser Arg Leu Met Thr Tyr Leu Arg 335 340 345 Gly He Ser Tyr Lys Val Thr Val Gly Thr Leu Val Ala Asn Glu 350 355 360 Gly Trp Asn Ala Ser Glu Asp Ala Leu Thr Ala Val He Thr Ala 365 370 375 Ala Tyr Leu Thr He Cys His Gin Arg Tyr Leu Arg Thr Gin Ala 380 385 390 He Ser Lys Gly Met Arg Arg Leu Glu Arg Glu His Ala Gin Lys 395 400 405 Phe He Thr Arg Leu Tyr Ser Trp Leu Phe Glu Lys Ser Gly Arg 410 415 420 Asp Tyr He Pro Gly Arg Gin Leu Glu Phe Tyr Ala Gin Cys Arg 425 430 435 Arg Trp Leu Ser Ala Gly Phe His Leu Asp Pro Arg Val Leu Val 440 445 450 Phe Asp Glu Ser Ala Pro Cys His Cys Arg Thr Ala He Arg Lys 455 460 465 Ala Val Ser Lys Phe Cys Cys Phe Met Lys Trp Leu Gly Gin Glu 470 475 480 Cys Thr Cys Phe Leu Gin Pro Ala Glu Gly Val Val Gly Asp Gin 485 490 495 Gly His Asp Asn Glu Ala Tyr Glu Gly Ser Asp Val Asp Pro Ala 500 505 510 Glu Ser Ala He Ser Asp He Ser Gly Ser Tyr Val Val Pro Gly 515 520 525 Thr Ala Leu Gin Pro Leu Tyr Gin Ala Leu Asp Leu Pro Ala Glu 530 535 540 He Val Ala Arg Ala Gly Arg Leu Thr Ala Thr Val Lys Val Ser 545 550 555 Gin Val Asp Gly Arg He Asp Cys Glu Thr Leu Leu Gly Asn Lys 560 • 565 570 Thr Phe Arg Thr Ser Phe Val Asp Gly Ala Val Leu Glu Thr Asn 575 580 585 Gly Pro Glu Arg His Asn Leu Ser Phe Asp Ala Ser Gin Ser Thr 590 595 600 Met Ala Ala Gly Pro Phe Ser Leu Thr Tyr Ala Ala Ser Ala Ala 605 610 615 Gly Leu Glu Val Arg Tyr Val Ala Ala Gly Leu Asp His Arg Ala 620 625 630 Val Phe Ala Pro Gly Val Ser Pro Arg Ser Ala Pro Gly Glu Val 635 640 645 Thr Ala Phe Cys Ser Ala Leu Tyr Arg Phe Asn Arg Glu Ala Gin 650 655 660 Arg Leu Ser Leu Thr Gly Asn Phe Trp Phe His Pro Glu Gly Leu 665 670 675 Leu Gly Pro Phe Ala Pro Phe Ser Pro Gly His Val Trp Glu Ser 680 685 690 Ala Asn Pro Phe Cys Gly Glu Ser Thr Leu Tyr Thr Arg Thr Trp 695 700 705 Ser Glu Val Asp Ala Val Pro Ser Pro Ala Gin Pro Asp Leu Gly 710 715 720 Phe Thr Ser Glu Pro Ser He Pro Ser Arg Ala Ala Thr Pro Thr 725 730 735 Pro Ala Ala Pro Leu Pro Pro Pro Ala Pro Asp Pro Ser Pro Thr 740 745 750 Leu Ser Ala Pro Ala Arg Gly Glu Pro Ala Pro Gly Ala Thr Ala 755 760 765 Arg Ala Pro Ala He Thr His Gin Thr Ala Arg His Arg Arg Leu 770 775 780 Leu Phe Thr Tyr Pro Asp Gly Ser Lys Val Phe Ala Gly Ser Leu 785 790 795 Phe Glu Ser Thr Cys Thr Trp Leu Val Asn Ala Ser Asn Val Asp 800 805 810 His Arg Pro Gly Gly Gly Leu Cys His Ala Phe Tyr Gin Arg Tyr 815 820 825 Pro Ala Ser Phe Asp Ala Ala Ser Phe Val Met Arg Asp Gly Ala 830 835 840 Ala Ala Tyr Thr Leu Thr Pro Arg Pro He He His Ala Val Ala 845 850 855 Pro Asp Tyr Arg Leu Glu His Asn Pro Lys Arg Leu Glu Ala Ala 860 865 870 Tyr Arg Glu Thr Cys Ser Arg Leu Gly Thr Ala Ala Tyr Pro Leu 875 » 880 885 Leu Gly Thr Gly He Tyr Gin Val Pro He Gly Pro Ser Phe Asp 890 895 900 Ala Trp Glu Arg Asn His Arg Pro Gly Asp Glu Leu Tyr Leu Pro 905 910 915 Glu Leu Ala Ala Arg Trp Phe Glu Ala Asn Arg Pro Thr Cys Pro 920 925 930 Thr Leu Thr He Thr Glu Asp Val Ala Arg Thr Ala Asn Leu Ala 935 940 945 He Glu Leu Asp Ser Ala Thr Asp Val Gly Arg Ala Cys Ala Gly 950 955 960 Cys Arg Val Thr Pro Gly Val Val Gin Tyr Gin Phe Thr Ala Gly 965 970 975 Val Pro Gly Ser Gly Lys Ser Arg Ser He Thr Gin Ala Asp Val 980 985 990 Asp Val Val Val Val Pro Thr Arg Glu Leu Arg Asn Ala Trp Arg 995 1000 1005 Arg Arg Gly Phe Ala Ala Phe Thr Pro His Thr Ala Ala Arg Val 1010 1015 1020 Thr Gin Gly Arg Arg Val Val He Asp Glu Ala Pro Ser Leu Pro 1025 1030 1035 Pro His Leu Leu Leu Leu His Met Gin Arg Ala Ala Thr Val His 1040 1045 1050 Leu Leu Gly Asp Pro Asn Gin He Pro Ala He Asp Phe Glu His 1055 1060 1065 Ala Gly Leu Val Pro Ala He Arg Pro Asp Leu Ala Pro Thr Ser 1070 1075 1080 Trp Trp His Val Thr His Arg Cys Pro Ala Asp Val Cys Glu Leu 1085 1090 1095 He Arg Gly Ala Tyr Pro Met He Gin Thr Thr Ser Arg Val Leu 1100 1105 1110 Arg Ser Leu Phe Trp Gly Glu Pro Ala Val Gly Gin Lys Leu Val 1115 1120 1125 Phe Thr Gin Ala Ala Lys Ala Ala Asn Pro Gly Ser Val Thr Val 1130 1135 1140 His Glu Ala Gin Gly Ala Thr Tyr Thr Glu Thr Thr He He Ala 1145 1150 1155 Thr Ala Asp Ala Arg Gly Leu He Gin Ser Ser Arg Ala His Ala 1160 1165 1170 He Val Ala Leu Thr Arg His Thr Glu Lys Cys Val He He Asp 1175 1180 1185 Ala Pro Gly Leu Leu Arg Glu Val Gly He Ser Asp Ala He Val 1190 . 1195 1200 Asn Asn Phe Phe Leu Ala Gly Gly Glu He Gly His Gin Arg Pro 1205 1210 1215 Ser Val He Pro Arg Gly Asn Pro Asp Ala Asn Val Asp Thr Leu 1220 1225 1230 Ala Ala Phe Pro Pro Ser Cys Glu He Ser Ala Phe His Glu Leu 1235 1240 1245 Ala Glu Glu Leu Gly His Arg Pro Ala Pro Val Ala Ala Val Leu 1250 1255 1260 Lys Leu Lys Val Asp Phe Arg Pro He Gly Leu Tyr Ala Gly Val 1580 1585 1590 Val Val Ala Pro Gly Leu Gly Ala Leu Pro Asp Val Val Arg Phe 1595 1600 1605 Ala Gly Arg Leu Thr Glu Lys Asn Trp Gly Pro Gly Pro Glu Arg 1610 1615 1620 Ala Glu Gin Leu Arg Leu Ala Val Ser Asp Phe Leu Arg Lys Leu 1625 1630 1635 Thr Asn Val Ala Gin Met Cys Val Asp Val Val Ser Arg Val Tyr 1640 1645 1650 Gly Val Ser Pro Gly Leu Val His Asn Leu He Glu Met Leu Gin 1655 1660 1665 Ala Val Ala Asp Gly Lys Ala His Phe Thr Glu Ser Val Lys Pro 1670 1675 1680 Val Leu Asp Leu Thr Asn Ser He Leu Cys Arg Val Glu 1685 1690 (SEQ. ID NO. : 2) Met Arg Pro Arg Pro He Leu Leu Leu Leu Leu Met Phe Leu Pro 1 5 10 15 Met Leu Pro Ala Pro Pro Pro Gly Gin Pro Ser Gly Arg Arg Arg 20 25 30 Gly Arg Arg Ser Gly Gly Ser Gly Gly Gly Phe Trp Gly Asp Arg 35 40 45 Val Asp Ser Gin Pro Phe Ala He Pro Tyr He His Pro Thr Asn 50 55 60 Pro Phe Ala Pro Asp Val Thr Ala Ala Ala Gly Ala Gly Pro Arg 65 70 75 Val Arg Gin Pro Ala Arg Pro Leu Gly Ser Ala Trp Arg Asp Gin 80 85 90 Ala Gin Arg Pro Ala Ala Ala Ser Arg Arg Arg Pro Thr Thr Ala 95 100 105 Gly Ala Ala Pro Leu Thr Ala Val Ala Pro Ala His Asp Thr Pro 110 t 115 120 Pro Val Pro Asp Val Asp Ser Arg Gly Ala He Leu Arg Arg Gin 125 130 135 Tyr Asn Leu Ser Thr Ser Pro Leu Thr Ser Ser Val Ala Thr Gly 140 145 150 Thr Asn Leu Val Leu Tyr Ala Ala Pro Leu Ser Pro Leu Leu Pro 155 160 165 Leu Gin Asp Gly Thr Asn Thr His He Met Ala Thr Glu Ala Ser 170 175 180 Asn Tyr Ala Gin Tyr Arg Val Ala Arg Ala Thr He Arg Tyr Arg 185 190 195 Pro Leu Val Pro Asn Ala Val Gly Gly Tyr Ala He Ser He Ser 200 205 210 Phe Typ Pro Gin Thr Thr Thr Thr Pro Thr Ser Val Asp Met Asn 215 220 225 Ser He Thr Ser Thr Asp Val Arg He Leu Val Gin Pro Gly He 230 235 240 Ala Ser Glu Leu Val He Pro Ser Glu Arg Leu His Tyr Arg Asn 245 250 255 Gin Gly Trp Arg Ser Val Glu Thr Ser Gly Val Ala Glu Glu Glu 260 265 270 Ala Thr Ser Gly Leu Val Met Leu Cys He His Gly Ser Pro Val 275 280 285 Asn Ser Tyr Thr Asn Thr Pro Tyr Thr Gly Ala Leu Gly Leu Leu 290 295 300 Asp Phe Ala Leu Glu Leu Glu Phe Arg Asn Leu Thr Pro Gly Asn 305 310 315 Thr Asn Thr Arg Val Ser Arg Tyr Ser Ser Thr Ala Arg His Arg 320 325 330 Leu Arg Arg Gly Ala Asp Gly Thr Ala Glu Leu Thr Thr Thr Ala 335 340 345 Ala Thr Arg Phe Met Lys Asp Leu Tyr Phe Thr Ser Thr Asn Gly 350 355 360 Val Gly Glu He Gly Arg Gly He Ala Leu Thr Leu Phe Asn Leu 365 370 375 Ala Asp Thr Leu Leu Gly Gly Leu Pro Thr Glu Leu He Ser Ser 380 385 390 Ala Gly Gly Gin Leu Phe Tyr Ser Arg Pro Val Val Ser Ala Asn 395 400 405 Gly Glu Pro Thr Val Lys Leu Tyr Thr Ser Val Glu Asn Ala Gin 410 415 420 Gin Asp Lys Gly He Ala He Pro His Asp He Asp Leu Gly Glu 425 430 435 Ser Arg Val Val He Gin Asp Tyr Asp Asn Gin His Glu Gin Asp 440 • 445 450 Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro Phe Ser Val Leu 455 460 465 Arg Ala Asn Asp Val Leu Trp Leu Ser Leu Thr Ala Ala Glu Tyr 470 475 480 Asp Gin Ser Thr Tyr Gly Ser Ser Thr Gly Pro Val Tyr Val Ser 485 490 495 Asp Ser Val Thr Leu Val Asn Val Ala Thr Gly Ala Gin Ala Val 500 505 510 He Leu Ser Pro Ser Gin Ser Pro He Phe He Gin Pro Thr Pro 65 70 75 Ser Pro Pro Met Ser Pro Leu Arg Pro Gly Leu Asp Leu Val Phe 80 t 85 90 Ala Asn Pro Pro Asp His Ser Ala Pro Leu Gly Val Thr Arg Pro 95 100 105 Ser Ala Pro Pro Leu Pro His Val Val Asp Leu Pro Gin Leu Gly 110 115 120 Pro Arg Arg The three-letter abbreviations follow the conventional amino acid shorthand for the twenty naturally occurring amino acids. The preferred recombinant HEV proteins consist of at least one ORF protein. Other recombinant proteins made up of more than one of the same or different ORF proteins may be made to alter the biological properties of the protein. It is contemplated that additions, substitutions or deletions of discrete amino acids or of discrete sequences of amino acids may enhance the biological activity of the HEV proteins. The present invention is also a nucleic acid sequence which is capable of directing the production of the above- discussed HEV protein or proteins substantially homologous to the HEV proteins. This nucleic acid sequence, designated SAR-55, is set both below as SEQ ID NO. : 4 and was deposited with the American Type Culture Collection (ATCC) on September 17, 1992. AGGCAGACCA CATATGTGGT CGATGCCATG GAGGCCCATC AGTTTATCAA 5 GGCTCCTGGC ATCACTACTG CTATTGAGCA GGCTGCTCTA GCAGCGGCCA 10 ACTCTGCCCT TGCGAATGCT GTGGTAGTTA GGCCTTTTCT CTCTCACCAG 15 CAGATTGAGA TCCTTATTAA CCTAATGCAA CCTCGCCAGC TTGTTTTCCG 20 CCCCGAGGTT TTCTGGAACC ATCCCATCCA GCGTGTTATC CATAATGAGC 25 TGGAGCTTTA CTGTCGCGCC CGCTCCGGCC GCTGCCTCGA AATTGGTGCC 30 CACCCCCGCT CAATAAATGA CAATCCTAAT GTGGTCCACC GTTGCTTCCT 35 CCGTCCTGCC GGGCGTGATG TTCAGCGTTG GTATACTGCC CCTACCCGCG 40 GGCCGGCTGC TAATTGCCGG CGTTCCGCGC TGCGCGGGCT CCCCGCTGCT 45 GACCGCACTT ACTGCTTCGA CGGGTTTTCT GGCTGTAACT TTCCCGCCGA 50 GACGGGCATC GCCCTCTATT CTCTCCATGA TATGTCACCA TCTGATGTCG 55 CCGAGGCTAT GTTCCGCCAT GGTATGACGC GGCTTTACGC TGCCCTCCAC 60 CTCCCGCCTG AGGTCCTGTT GCCCCCTGGC ACATACCGCA CCGCGTCGTA 65 CTTGCTGATC CATGACGGCA GGCGCGTTGT GGTGACGTAT GAGGGTGACA 70 CTAGTGCTGG TTATAACCAC GATGTTTCCA ACCTGCGCTC CTGGATTAGA 75 ACCACTAAGG TTACCGGAGA CCACCCTCTC GTCATCGAGC GGGTTAGGGC 80 CATTGGCTGC CACTTTGTCC TTTTACTCAC GGCTGCTCCG GAGCCATCAC 85 CTATGCCCTA TGTCCCTTAC CCCCGGTCTA CCGAGGTCTA TGTCCGATCG 90 ATCTTCGGCC CGGGTGGCAC CCCCTCCCTA TTTCCAACCT CATGCTCCAC 95 CAAGTCGACC TTCCATGCTG TCCCTGCCCA TATCTGGGAC CGTCTCATGT 100 TGTTCGGGGC CACCCTAGAT GACCAAGCCT TTTGCTGCTC CCGCCTAATG 105 ACTTACCTCC GCGGCATTAG CTACAAGGTT ACTGTGGGCA CCCTTGTTGC 1100 CAATGAAGGC TGGAACGCCT CTGAGGACGC TCTTACAGCT GTCATCACTG 1150 CCGCCTACCT TACCATCTGC CACCAGCGGT ACCTCCGCAC TCAGGCTATA 1200 TCTAAGGGGA TGCGTCGCCT GGAGCGGGAG CATGCTCAGA AGTTTATAAC 1250 ACGCCTCTAC AGTTGGCTCT TTGAGAAGTC CGGCCGTGAT TATATCCCCG 1300 GCCGTCAGTT GGAGTTCTAC GCTCAGTGTA GGCGCTGGCT CTCGGCCGGC 1350 TTTCATCTTG ACCCACGGGT GTTGGTTTTT GATGAGTCGG CCCCCTGCCA 1400 CTGTAGGACT GCGATTCGTA AGGCGGTCTC AAAGTTTTGC TGCTTTATGA 1450 AGTGGCTGGG CCAGGAGTGC ACCTGTTTTC TACAACCTGC AGAAGGCGTC 1500 GTTGGCGACC AGGGCCATGA CAACGAGGCC TATGAGGGGT CTGATGTTGA 1550 CCCTGCTGAA TCCGCTATTA GTGACATATC TGGGTCCTAC GTAGTCCCTG 1600 GCACTGCCCT CCAACCGCTT TACCAAGCCC TTGACCTCCC CGCTGAGATT 1650 GTGGCTCGTG CAGGCCGGCT GACCGCCACA GTAAAGGTCT CCCAGGTCGA 1700 CGGGCGGATC GATTGTGAGA CCCTTCTCGG TAATAAAACC TTCCGCACGT 1750 CGTTTGTTGA CGGGGCGGTT TTAGAGACTA ATGGCCCAGA GCGCCACAAT 1800 CTCTCTTTTG ATGCCAGTCA GAGCACTATG GCCGCCGGCC CTTTCAGTCT 1850 CACCTATGCC GCCTCTGCTG CTGGGCTGGA GGTGCGCTAT GTCGCCGCCG 1900 GGCTTGACCA CCGGGCGGTT TTTGCCCCCG GCGTTTCACC CCGGTCAGCC 1950 CCTGGCGAGG TCACCGCCTT CTGTTCTGCC CTATACAGGT TTAATCGCGA 2000 GGCCCAGCGC CTTTCGCTGA CCGGTAATTT TTGGTTCCAT CCTGAGGGGC 2050 TCCTTGGCCC CTTTGCCCCG TTTTCCCCCG GGCATGTTTG GGAGTCGGCT 2100 AATCCATTCT GTGGCGAGAG CACACTTTAC ACCCGCACTT GGTCGGAGGT 2150 TGATGCTGTT CCTAGTCCAG CCCAGCCCGA CTTAGGTTTT ACATCTGAGC 2200 CTTCTATACC TAGTAGGGCC GCCACACCTA CCCCGGCGGC CCCTCTACCC 2250 CCCCCTGCAC CGGATCCTTC CCCTACTCTC TCTGCTCCGG CGCGTGGTGA 2300 GCCGGCTCCT GGCGCTACCG CCAGGGCCCC AGCCATAACC CACCAGACGG 2350 CCCGGCATCG CCGCCTGCTC TTTACCTACC CGGATGGCTC TAAGGTGTTC 2400 GCCGGCTCGC TGTTTGAGTC GACATGTACC TGGCTCGTTA ACGCGTCTAA 2450 TGTTGACCAC CGCCCTGGCG GTGGGCTCTG TCATGCATTT TACCAGAGGT 2500 ACCCCGCCTC CTTTGATGCT GCCTCTTTTG TGATGCGCGA CGGCGCGGCC 2550 GCCTACACAT TAACCCCCCG GCCAATAATT CATGCCGTCG CTCCTGATTA 2600 TAGGTTGGAA CATAACCCAA AGAGGCTTGA GGCTGCCTAC CGGGAGACTT 2650 GCTCCCGCCT CGGTACCGCT GCATACCCAC TCCTCGGGAC CGGCATATAC 2700 CAGGTGCCGA TCGGTCCCAG TTTTGACGCC TGGGAGCGGA ATCACCGCCC 2750 CGGGGACGAG TTGTACCTTC CTGAGCTTGC TGCCAGATGG TTCGAGGCCA 2800 ATAGGCCGAC CTGCCCAACT CTCACTATAA CTGAGGATGT TGCGCGGACA 2850 GCAAATCTGG CTATCGAACT TGACTCAGCC ACAGACGTCG GCCGGGCCTG 290 TGCCGGCTGT CGAGTCACCC CCGGCGTTGT GCAGTACCAG TTTACCGCAG 295 GTGTGCCTGG ATCCGGCAAG TCCCGCTCTA TTACCCAAGC CGACGTGGAC 300 GTTGTCGTGG TCCCGACCCG GGAGTTGCGT AATGCCTGGC GCCGCCGCGG 305 CTTCGCTGCT TTCACCCCGC ACACTGCGGC TAGAGTCACC CAGGGGCGCC 310 GGGTTGTCAT TGATGAGGCC CCGTCCCTTC CCCCTCATTT GCTGCTGCTC 315 CACATGCAGC GGGCCGCCAC CGTCCACCTT CTTGGCGACC CGAATCAGAT 320 CCCAGCCATC GATTTTGAGC ACGCCGGGCT CGTTCCCGCC ATCAGGCCCG 325 ATTTGGCCCC CACCTCCTGG TGGCATGTTA CCCATCGCTG CCCTGCGGAT 330 GTATGTGAGC TAATCCGCGG CGCATACCCT ATGATTCAGA CCACTAGTCG 335 GGTCCTCCGG TCGTTGTTCT GGGGTGAGCC CGCCGTTGGG CAGAAGCTAG 340 TGTTCACCCA GGCGGCTAAG GCCGCCAACC CCGGTTCAGT GACGGTCCAT 345 GAGGCACAGG GCGCTACCTA CACAGAGACT ACCATCATTG CCACGGCAGA 350 TGCTCGAGGC CTCATTCAGT CGTCCCGAGC TCATGCCATT GTTGCCTTGA 355 CGCGCCACAC TGAGAAGTGC GTCATCATTG ACGCACCAGG CCTGCTTCGC 360 GAGGTGGGCA TCTCCGATGC AATCGTTAAT AACTTTTTCC TTGCTGGTGG 365 CGAAATTGGC CACCAGCGCC CATCTGTTAT CCCTCGCGGC AATCCTGACG 370 CCAATGTTGA CACCTTGGCT GCCTTCCCGC CGTCTTGCCA GATTAGCGCC 375 TTCCATCAGT TGGCTGAGGA GCTTGGCCAC AGACCTGCCC CTGTCGCGGC 380 TGTTCTACCG CCCTGCCCTG AGCTTGAACA GGGCCTTCTC TACCTGCCCC 385 AAGAACTCAC CACCTGTGAT AGTGTCGTAA CATTTGAATT AACAGATATT 390 GTGCATTGTC GTATGGCCGC CCCGAGCCAG CGCAAGGCCG TGCTGTCCAC 395 GCTCGTGGGC CGTTATGGCC GCCGCACAAA GCTCTACAAT GCCTCCCACT 400 CTGATGTTCG CGACTCTCTC GCCCGTTTTA TCCCGGCCAT TGGCCCCGTA 405 CAGGTTACAA CCTGTGAATT GTACGAGCTA GTGGAGGCCA TGGTCGAGAA 410 GGGCCAGGAC GGCTCCGCCG TCCTTGAGCT CGACCTTTGT AGCCGCGACG 415 TGTCCAGGAT CACCTTCTTC CAGAAAGATT GTAATAAATT CACCACGGGG 420 GAGACCATCG CCCATGGTAA AGTGGGCCAG GGCATTTCGG CCTGGAGTAA 425 GACCTTCTGT GCCCTTTTCG GCCCCTGGTT CCGTGCTATT GAGAAGGCTA 430 TCCTGGCCCT GCTCCCTCAG GGTGTGTTTT ATGGGGATGC CTTTGATGAC 435 ACCGTCTTCT CGGCGGCTGT GGCCGCAGCA AAGGCATCCA TGGTGTTCGA 440 GAATGACTTT TCTGAGTTTG ATTCCACCCA GAATAATTTT TCCTTGGGCC 445 TAGAGTGTGC TATTATGGAG GAGTGTGGGA TGCCGCAGTG GCTCATCCGC 450 TTGTACCACC TTATAAGGTC TGCGTGGATT CTGCAGGCCC CGAAGGAGTC 455 CCTGCGAGGG TTTTGGAAGA AACACTCCGG TGAGCCCGGC ACCCTTCTGT 460 GGAATACTGT CTGGAACATG GCCGTTATCA CCCACTGTTA TGATTTCCGC 465 GATCTGCAGG TGGCTGCCTT TAAAGGTGAT GATTCGATAG TGCTTTGCAG 470 TGAGTACCGT CAGAGCCCAG GGGCTGCTGT CCTGATTGCT GGCTGTGGCC 475 TAAAGTTGAA GGTGGATTTC CGTCCGATTG GTCTGTATGC AGGTGTTGTG 480 GTGGCCCCCG GCCTTGGCGC GCTTCCTGAT GTCGTGCGCT TCGCCGGTCG 485 GCTTACTGAG AAGAATTGGG GCCCTGGCCC CGAGCGGGCG GAGCAGCTCC 490 GCCTCGCTGT GAGTGATTTT CTCCGCAAGC TCACGAATGT AGCTCAGATG 495 TGTGTGGATG TTGTCTCTCG TGTTTATGGG GTTTCCCCTG GGCTCGTTCA 500 TAACCTGATT GGCATGCTAC AGGCTGTTGC TGATGGCAAG GCTCATTTCA 505 CTGAGTCAGT GAAGCCAGTG CTTGACCTGA CAAATTCAAT TCTGTGTCGG 510 GTGGAATGAA TAACATGTCT TTTGCTGCGC CCATGGGTTC GCGACCATGC 515 GCCCTCGGCC TATTTTGCTG TTGCTCCTCA TGTTTCTGCC TATGCTGCCC 520 GCGCCACCGC CCGGTCAGCC GTCTGGCCGC CGTCGTGGGC GGCGCAGCGG 525 CGGTTCCGGC GGTGGTTTCT GGGGTGACCG GGTTGATTCT CAGCCCTTCG 530 CAATCCCCTA TATTCATCCA ACCAACCCCT TCGCCCCCGA TGTCACCGCT 535 GCGGCCGGGG CTGGACCTCG TGTTCGCCAA CCCGCCCGAC CACTCGGCTC 540 CGCTTGGCGT GACCAGGCCC AGCGCCCCGC CGCTGCCTCA CGTCGTAGAC 545 CTACCACAGC TGGGGCCGCG CCGCTAACCG CGGTCGCTCC GGCCCATGAC 550 ACCCCGCCAG TGCCTGATGT TGACTCCCGC GGCGCCATCC TGCGCCGGCA 555 GTATAACCTA TCAACATCTC CCCTCACCTC TTCCGTGGCC ACCGGCACAA 560 ATTTGGTTCT TTACGCCGCT CCTCTTAGCC CGCTTCTACC CCTCCAGGAC 565 GGCACCAATA CTCATATAAT GGCTACAGAA GCTTCTAATT ATGCCCAGTA 570 CCGGGTTGCT CGTGCCACAA TTCGCTACCG CCCGCTGGTC CCCAACGCTG 575 TTGGTGGCTA CGCTATCTCC ATTTCGTTCT GGCCACAGAC CACCACCACC 580 CCGACGTCCG TTGACATGAA TTCAATAACC TCGACGGATG TCCGTATTTT 585 AGTCCAGCCC GGCATAGCCT CCGAGCTTGT TATTCCAAGT GAGCGCCTAC 590 ACTATCGCAA CCAAGGTTGG CGCTCTGTTG AGACCTCCGG GGTGGCGGAG 595 GAGGAGGCCA CCTCTGGTCT TGTCATGCTC TGCATACATG GCTCACCTGT 600 AAATTCTTAT ACTAATACAC CCTATACCGG TGCCCTCGGG CTGTTGGACT 605 TTGCCCTCGA ACTTGAGTTC CGCAACCTCA CCCCCGGTAA TACCAATACG 610 CGGGTCTCGC GTTACTCCAG CACTGCCCGT CACCGCCTTC GTCGCGGTGC 615 AGATGGGACT GCCGAGCTCA CCACCACGGC TGCTACTCGC TTCATGAAGG 620 ACCTCTATTT TACTAGTACT AATGGTGTTG GTGAGATCGG CCGCGGGATA 625 GCGCTTACCC TGTTTAACCT TGCTGACACC CTGCTTGGCG GTCTACCGAC 630 AGAATTGATT TCGTCGGCTG GTGGCCAGCT GTTCTACTCT CGCCCCGTCG 635 TCTCAGCCAA TGGCGAGCCG ACTGTTAAGC TGTATACATC TGTGGAGAAT 640 GCTCAGCAGG ATAAGGGTAT TGCAATCCCG CATGACATCG ACCTCGGGGA 645 ATCCCGTGTA GTTATTCAGG ATTATGACAA CCAACATGAG CAGGACCGAC 650 CGACACCTTC CCCAGCCCCA TCGCGTCCTT TTTCTGTCCT CCGAGCTAAC 655 GATGTGCTTT GGCTTTCTCT CACCGCTGCC GAGTATGACC AGTCCACTTA 6600 CGGCTCTTCG ACCGGCCCAG TCTATGTCTC TGACTCTGTG ACCTTGGTTA 665 ATGTTGCGAC CGGCGCGCAG GCCGTTGCCC GGTCACTCGA CTGGACCAAG 6700 GTCACACTTG ATGGTCGCCC CCTTTCCACC ATCCAGCAGT ATTCAAAGAC 6750 CTTCTTTGTC CTGCCGCTCC GCGGTAAGCT CTCCTTTTGG GAGGCAGGAA 6800 CTACTAAAGC CGGGTACCCT TATAATTATA ACACCACTGC TAGTGACCAA 6850 CTGCTCGTTG AGAATGCCGC TGGGCATCGG GTTGCTATTT CCACCTACAC 6900 TACTAGCCTG GGTGCTGGCC CCGTCTCTAT TTCCGCGGTT GCTGTTTTAG 6950 CCCCCCACTC TGTGCTAGCA TTGCTTGAGG ATACCATGGA CTACCCTGCC 7000 CGCGCCCATA CTTTCGATGA CTTCTGCCCG GAGTGCCGCC CCCTTGGCCT 7050 CCAGGGTTGT GCTTTTCAGT CTACTGTCGC TGAGCTTCAG CGCCTTAAGA 7100 TGAAGGTGGG TAAAACTCGG GAGTTATAGT TTATTTGCTT GTGCCCCCCT 7150 TCTTTCTGTT GCTTATTT 7168 The abbreviations used for the nucleotides are those standardly used in the art. The sequence in one direction has been designated by convention as the "plus" sequence since it is the protein- encoding strand of RNA viruses and this is the sequence shown above as SEQ ID. NO.:4. The deduced amino acid sequences of the open reading frames of SAR-55 have SEQ ID NO. 1, SEQ ID NO. 2, and SEQ ID NO. 3. ORF-1 starts at nucleotide 28 of SEQ. ID NO. 4 and extends 5078 nucleotides; ORF-2 starts at nucleotide 5147 of SEQ. ID NO. 4 and extends 1979 nucleotides; and ORF-3 starts at nucleotide 5106 of SEQ. ID NO. 4 and extends 368 nucleotides. Variations are contemplated in the DNA sequence which will result in a DNA sequence that is capable of directing production of analogs of the ORF-2 protein. It should be noted that the DNA sequence set forth above represents a preferred embodiment of the present invention. Due to the degeneracy of the genetic code, it is to be understood that numerous choices of nucleotides may be made that will lead to a DNA sequence capable of directing production of the instant ORF proteins or their analogs. As such, DNA sequences which are functionally equivalent to the sequences set forth above or which are functionally equivalent to sequences that would direct production of analogs of the ORF proteins produced pursuant to the amino acid sequence set forth above, are intended to be encompassed within the present invention. The present invention relates to a method for detecting the hepatitis E virus in biological samples based on selective amplification of hepatitis E gene fragments. Preferably, this method utilizes a pair of single-stranded primers derived from non-homologous regions of opposite strands of a DNA duplex fragment, which in turn is derived from a hepatitis E virus whose genome contains a region homologous to the SAR-55 sequence shown in SEQ ID No.: 4. These primers can be used in a method following the process for amplifying selected nucleic acid sequences as defined in U.S. Patent No. 4,683,202. The present invention also relates to the use of single-stranded antisense poly-or oligonucleotides derived from sequences homologous to the SAR-55 cDNA to inhibit the expression of hepatitis E genes. These anti-sense poly-or oligonucleotides can be either DNA or RNA. The targeted sequence is typically messenger RNA and more preferably, a signal sequence Required for processing or translation of the RNA. The antisense poly-or oligonucleotides can be conjugated to a polycation such as polylysine as disclosed in Lemaitre, M. et al. (1989) Proc Natl Acad Sci USA 84:648-652; and this conjugate can be administered to a mammal in an amount sufficient to hybridize to and inhibit the function of the messenger RNA. The present invention includes a recombinant DNA method for the manufacture of HEV proteins, preferably a protein composed of at least one ORF protein, most preferably at least one ORF-2 protein. The recombinant ORF protein may be composed of one ORF protein or a combination of the same or different ORF proteins. A natural or synthetic nucleic acid sequence may be used to direct production of the HEV proteins. In one embodiment of the invention, the method comprises: (a) preparation of a nucleic acid sequence capable of directing a host organism to produce a protein of HEV; (b) cloning the nucleic acid sequence into a vector capable of being transferred into and replicated in a host organism, such vector containing operational elements for the nucleic acid sequence; (c) transferring the vector containing the nucleic acid and operational elements into a host organism capable of expressing the protein; (d) culturing the host organism under conditions appropriate for amplification of the vector and expression of the protein; and (e) harvesting the protein. In another embodiment of the invention, the method for the recombinant DNA synthesis of a protein encoded by nucleic acids of HEV, preferably encoding by at least one ORF of HEV or a combination of the same or different ORF proteins, most preferably encoding at least one ORF-2 nucleic acid sequence, comprises: (a) culturing a transformed or transfected host organism containing a nucleic acid sequence capable of directing the host organism to produce a protein, under conditions such that the protein is produced, said protein exhibiting substantial homology to a native HEV protein isolated from HEV having the amino acid sequence according to SEQ ID NO. 1, SEQ ID NO. 2 or SEQ ID NO. 3, or combina¬ tions thereof. In one embodiment, the RNA sequence of the viral genome of HEV strain SAR-55 was isolated and cloned to CDNA as follows. Viral RNA is extracted from a biological sample collected from cynomolgus monkeys infected with SAR-55 and the viral RNA is then reverse transcribed and amplified by poly erase chain reaction using primers complementary to the plus or minus strands of the genome of a strain of HEV from Burma (Tarn et al.) or the SAR-55 genome. The PCR fragments are subcloned into pBR322 or pGEM-32 and the double-stranded PCR fragments were sequenced. The vectors contemplated for use in the present invention include any vectors into which a nucleic acid sequence as described above can be inserted, along with any preferred or required operational elements, and which vector can then be subsequently transferred into a host organism and replicated in such organism. Preferred vectors are those whose restriction sites have been well documented and which contain the operational elements pre¬ ferred or required for transcription of the nucleic acid sequence. The "operational elements" as discussed herein include at least one promoter, at least one operator, at least one leader sequence, at least one terminator codon, and any other DNA sequences necessary or preferred for appropriate transcription and subsequent translation of the vector nucleic acid. In particular, it is contemplated that such vectors will contain at least one origin of replication recognized by the host organism along with at least one selectable marker and at least one promoter sequence capable of initiating transcription of the nucleic acid sequence. In construction of the cloning vector of the present invention, it should additionally be noted that multiple copies of the nucleic acid sequence and its attendant operational elements may be inserted into each vector. In such an embodiment, the host organism would produce greater amounts per vector of the desired HEV protein. The number of multiple copies of the DNA sequence which may be inserted into the vector is limited only by the ability of the resultant vector due to its size, to be transferred into and replicated and transcribed in an appropriate host microorganism. In another embodiment, restriction digest fragments containing a coding sequence for HEV proteins can be inserted into a suitable expression vector that functions in prokaryotic or eukaryotic cells. By suitable is meant that the vector is capable of carrying and expressing a complete nucleic acid sequence coding for HEV proteins, preferably at least one complete ORF protein. In the case or ORF-2, the expressed protein should form viral-like particles. Preferred expression vectors are those that function in a eukaryotic cell. Examples of such vectors include but are not limited to vaccinia virus vectors, adenovirus or herpesviruses, preferably the baculovirus transfer vector, pBlueBac. Preferred vectors are p63-2, which contains the complete ORF-2 gene, and P59-4, which contains the complete ORF-3 and ORF-2 genes. These vectors were deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852 USA on September 10, 1992. Example 1 illustrates the cloning of the ORF-2 gene into Pbluebac to produce p63-2. This method includes digesting the genome of HEV strain SAR-55 with the restriction enzymes Nrul and Bglll, inserting a polylinker containing Blnl and. Bglll sites into the unique Nhel site of the vector and inserting the Nrul-Bglll ORF-2 fragment in Blnl-Bglll Pbluebac using an adapter. In yet another embodiment, the selected recombinant expression vector may then be transfected into a suitable eukaryotic cell system for purposes of expressing the recombinant protein. Such eukaryotic cell systems include but are not limited to cell lines such as HeLa, MRC-5 or Cv-1. A preferred eukaryotic cell system is SF9 insect cells. One preferred method involves use of the Pbluebac expression vector where the insect cell line SF9 is cotransfected with recombinant Pbluebac and AcMNPV baculovirus DNA by the Ca precipitation method. The expressed recombinant protein may be detected by methods known in the art which include Coomassie blue staining and Western blotting using sera containing anti- HEV antibody as shown in Example 2. Another method is the detection of virus-like particles by immunoelectron micro¬ scopy as shown in Example 3. In a further embodiment, the recombinant protein expressed by the SF9 cells can be obtained as a crude lysate or it can be purified by standard protein purification procedures known in the art which may include differential precipitation, molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis, affinity, and immunoaffinity chromatography and the like. In the case of immunoaffinity chromatography, the recombinant protein may be purified by passage through a column containing a resin which has bound thereto antibodies specific for the ORF protein. In another embodiment, the expressed recombinant proteins of this invention can be used in immunoassays for diagnosing or prognosing hepatitis E in a mammal including but not limited to humans, chimpanzees, Old World monkeys, New World monkeys, other primates and the like. In a preferred embodiment, the immunoassay is useful in diag¬ nosing hepatitis E infection in humans. Immunoassays using the HEV proteins, particularly the ORF proteins, and especially ORF 2 proteins, provide a highly specific, sensitive and reproducible method for diagnosing HEV infections, in contrast to immunoassays which utilize partial ORF proteins. Immunoassays of the present invention may be a radioim unoassay. Western blot assay, immunofluorescent assay, enzyme immunoassay, chemiluminescent assay, immunohistochemical assay and the like. Standard techniques known in the art for ELISA are described in Methods in Immunodiagnosis, 2nd Edition, Rose and Bigazzi, eds., John Wiley and Sons, 1980 and Campbell et al., Methods of Immunology. W.A. Benjamin, Inc., 1964, both of which are incorporated herein by reference. Such assays may be a direct, indirect, competitive, or noncompetitive immunoassay as described in the art. (Oellerich, M. 1984. J.Clin. Chem. Clin. BioChem. 22: 895-904) Biological samples appropriate for such detection assays include, but are not limited to, tissue biopsy extracts, whole blood, plasma, serum, cerebrospinal fluid, pleural fluid, urine and the like. In one embodiment, test serum is reacted with a solid phase reagent having surface-bound recombinant HEV protein as an antigen, preferably an ORF protein or combination of different ORF proteins such as ORF-2 and ORF-3, ORF-1 and ORF-3 and the like. More preferably, the HEV protein is an ORF-2 protein that forms virus-like particles. The solid surface reagent can be prepared by known techniques for attaching protein to solid support material. These attachment methods include non-specific adsorption of the protein to the support or covalent attachment of the protein to a reactive group on the support. After reaction of the antigen with anti-HEV antibody, unbound serum components are removed by washing and the antigen- antibody complex is reacted with a secondary antibody such as labelled anti-human antibody. The label may be an enzyme which is detected by incubating the solid support in the presence of a suitable fluorimetric or colorimetric reagent. Other detectable labels may also be used, such as radiolabels or colloidal gold, and the like. In a preferred embodiment, protein expressed by the recombinant vector Pbluebac containing the entire ORF-2 sequence of SAR-55 is used as a specific binding agent to detect anti-HEV antibodies, preferably IgG or IgM antibodies. Examples 4 and 5 show the results of an ELISA in which the solid phase reagent has recombinant ORF-2 as the surface antigen. This protein, encoded by the entire ORF-2 nucleic acid sequence, is superior to the partial ORF-2 proteins, as it is reactive with more antisera from different primate species infected with HEV than are partial antigens of ORF-2. The protein of the present invention is also capable of detecting antibodies produced in response to different strains of HEV but not to Hepatitis A, B, C or Hepatitis D. The HEV protein and analogs may be prepared in the form of a kit, alone, or in combinations with other reagents such as secondary antibodies, for use in immunoassays. The recombinant HEV proteins, preferably an ORF protein or combination of ORF proteins, more preferably an ORF-2 protein and substantially homologous proteins and analogs of the invention can be used as a vaccine to protect mammals against challenge with Hepatitis E. The vaccine, which acts as an immunogen, may be a cell, cell lysate from cells transfected with a recombinant expression vector or a culture supernatant containing the expressed protein. Alternatively, the immunogen is a partially or substantially purified recombinant protein. While it is possible for the immunogen to be administered in a pure or substantially pure form, it is preferable to present it as a pharmaceutical composition, formulation or preparation. The formulations of the present invention, both for veterinary and for human use, comprise an immunogen as described above, together with one or more pharmaceutically acceptable carriers and optionally other therapeutic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. The formulations may conveniently be presented in unit dosage form and may be prepared by any method well-known in the pharmaceutical art. All methods include the step of bringing into asso- ciation the active ingredient with the carrier which con¬ stitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired formulation. Formulations suitable for intravenous intramuscular, subcutaneous, or intraperitoneal administration, conveniently comprise sterile aqueous solutions of the active ingredient with solutions which are preferably isotonic with the blood of the recipient. Such formulations may be conveniently prepared by dissolving solid active ingredient in water containing physiologically compatible substances such as sodium chloride (e.g. 0.1-2.0M), glycine, and the like, and having a buffered Ph compatible with physiological conditions to produce an aqueous solution, and rendering said solution sterile. These may be present in unit or multi-dose containers, for example, sealed ampoules or vials. The formulations of the present invention may incor¬ porate a stabilizer. Illustrative stabilizers are poly¬ ethylene glycol, proteins, saccharides, amino acids, inor¬ ganic acids, and organic acids which may be used either on their own or as admixtures. These stabilizers are preferably incorporated in an amount of 0.11-10,000 parts by weight per part by weight of immunogen. If two or more stabilizers are to be used, their total amount is preferably within the range specified above. These stabilizers are used in aqueous solutions at the appropriate concentration and Ph. The specific osmotic pressure of such aqueous solutions is generally in the range of 0.1-3.0 osmoles, preferably in the range of 0.8- 1.2. The Ph of the aqueous solution is adjusted to be within the range of 5.0-9.0, preferably within the range of 6-8. In formulating the immunogen of the present invention, anti-adsorption agent may be used. Additional pharmaceutical methods may be employed to control the duration of action. Controlled release pre¬ parations may be achieved through the use of polymer to complex or absorb the proteins or their derivatives. The controlled delivery may be exercised by selecting appropriate macromolecules (for example polyester, polyamino acids, polyvinyl, pyrrolidone, ethylenevinylacetate, methylcellulose, carboxymethylcellulose, or protamine sulfate) and the con¬ centration of macromolecules as well as the methods of incorporation in order to control release. Another possible method to control the duration of action by controlled-release preparations is to incorporate the proteins, protein analogs or their functional derivatives, into particles of a polymeric material such as polyesters, polyamino acids, hydrogels, poly(lactic acid) or ethylene vinylacetate copolymers. Alternatively, instead of incorporating these agents into polymeric particles, it is possible to entrap these materials in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxy- methylcellulose or gelatin-microcapsules and poly(methylmethacylate) microcapsules, respectively, or in colloidal drug delivery systems, for example, liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules or in macroemulsions. When oral preparations are desired, the compositions may be combined with typical carriers, such as lactose, sucrose, starch, talc magnesium stearate, crystalline cellulose, methyl cellulose, carboxymethyl cellulose, glycerin, sodium alginate or gum arabic among others. The proteins of the present invention may be supplied in the form of a kit, alone, or in the form of a pharma¬ ceutical composition as described above. Vaccination can be conducted by conventional methods. For example, the immunogen can be used in a suitable diluent such as saline or water, or complete or incomplete adjuvants. Further, the immunogen may or may not be bound to a carrier to make the protein immunogenic. Examples of such carrier molecules include but are not limited to bovine serum albumin (BSA) , keyhole limpet hemocyanin (KLH) , tetanus toxoid, and the like. The immunogen can be administered by any route appropriate for antibody production such as intravenous, intraperitoneal, intramuscular, subcutaneous, and the like. The immunogen may be administered once or at periodic intervals until a significant titer of anti-HEV antibody is produced. The antibody may be detected in the serum using an immunoassay. The administration of the immunogen of the present invention may be for either a prophylactic or therapeutic purpose. When provided prophylactically, the immunogen is provided in advance of any exposure to HEV or in advance of any symptom due to HEV infection. The prophylactic administration of the immunogen serves to prevent or attenuate any subsequent infection of HEV in a mammal. When provided therapeutically, the immunogen is provided at (or shortly after) the onset of the infection or at the onset of any symptom of infection or disease caused by HEV. The therapeutic administration of the immunogen serves to attenuate the infection or disease. A preferred embodiment is a vaccine prepared using recombinant ORF-2 protein expressed by the ORF-2 sequence of HEV strain SAR-55 and equivalents thereof. Since the recombinant ORF-2 protein has already been demonstrated to be reactive with a variety of HEV-positive sera, their utility in protecting against a variety of HEV strains is indicated. In addition to use as a vaccine, the compositions can be used to prepare antibodies to HEV virus-like particles. The antibodies can be used directly as antiviral agents. To prepare antibodies, a host animal is immunized using the virus particles or, as appropriate, non-particle antigens native to the virus particle are bound to a carrier as described above for vaccines. The host serum or plasma is collected following an appropriate time interval to provide a composition comprising antibodies reactive with the virus particle. The gamma globulin fraction or the IgG antibodies can be obtained, for example, by use of saturated ammonium sulfate or DEAE Sephadex, or other techniques known to those skilled in the art. The antibodies are substantially free of many of the adverse side effects which may be associated with other anti-viral agents such as drugs. The antibody compositions can be made even more compatible with the host system by minimizing potential adverse immune system responses. This is accomplished by removing all or a portion of the Fc portion of a foreign species antibody or using an antibody of the same species as the host animal, for example, the use of antibodies from human/human hybridomas. Humanized antibodies (i.e., nonimmunogenic in a human) may be produced, for example, by replacing an immunogenic portion of an antibody with a corresponding, but nonimmunogenic portion (i.e., chimeric antibodies). Such chimeric antibodies may contain the reactive or antigen binding portion of an antibody from one species and the Fc portion of an antibody (nonimmunogenic) from a different species. Examples of chimeric antibodies, include but are not limited to, non- human mammal-human chimeras, rodent-human chimeras, murine-human and rat-human chimeras (Robinson et al.. International Patent Application 184,187; Taniguchi M. , European Patent Application 171,496; Morrison et al., European Patent Application 173,494; Neuberger et al., PCT Application WO 86/01533; Cabilly et al., 1987 Proc. Natl. Acad. Sci. USA 84:3439; Nishimura et al., 1987 Cane. Res. 47:999; Wood et al., 1985 Nature 314:446; Shaw et al., 1988 J. Natl. Cancer Inst. 80: 15553, all incorporated herein by reference) . General reviews of "humanized" chimeric antibodies are provided by Morrison S., 1985 Science 229:1202 and by Oi et al., 1986 BioTechniques 4:214. Suitable "humanized" antibodies can be alternatively produced by CDR or CEA substitution (Jones et al., 1986 Nature 321:552; Verhoeyan et al., 1988 Science 239:1534; Biedleret al. 1988 J. Immunol. 141:4053, all incorporated herein by reference) . The antibodies or antigen binding fragments may also be produced by genetic engineering. The technology for expression of both heavy and light cain genes in E. coli is the subject the PCT patent applications; publication number WO 901443, WO901443, and WO 9014424 and in Huse et al., 1989 Science 246:1275-1281. The antibodies can also be used as a means of enhancing the immune response. The antibodies can be administered in amounts similar to those used for other therapeutic administrations of antibody. For example, pooled gamma globulin is administered at 0.02-0.1 ml/lb body weight during the early incubation period of other viral diseases such as rabies, measles and hepatitis B to interfere with viral entry into cells. Thus, antibodies reactive with the HEV virus particle can be passively administered alone or in conjunction with another anti¬ viral agent to a host infected with an HEV to enhance the immune response and/or the effectiveness of an antiviral drug. Alternatively, anti-HEV antibodies can be induced by - 33 - administering anti-idiotype antibodies as immunogens. Conveniently, a purified anti-HEV antibody preparation prepared as described above is used to induce anti- idiotype antibody in a host animal. The composition is administered to the host animal in a suitable diluent. Following administration, usually repeated administration, the host produces anti-idiotype antibody. To eliminate an immunogenic response to the Fc region, antibodies produced by the same species as the host animal can be used or the FC region of the administered antibodies can be removed. Following induction of anti-idiotype antibody in the host animal, serum or plasma is removed to provide an antibody composition. The composition can be purified as described above for anti-HEV antibodies, or by affinity chroma¬ tography using anti-HEV antibodies bound to the affinity matrix. The anti-idiotype antibodies produced are similar in conformation to the authentic HEV-antigen and may be used to prepare an HEV vaccine rather than using an HEV particle antigen. When used as a means of inducing anti-HEV virus antibodies in an animal, the manner of injecting the anti¬ body is the same as for vaccination purposes, namely intramuscularly, intraperitoneally, subcutaneously or the like in an effective concentration in a physiologically suitable diluent with or without adjuvant. One or more booster injections may be desirable. The HEV derived proteins of the invention are also intended for use in producing % antiserum designed for pre- or post-exposure prophylaxis. Here an HEV protein, or mixture of proteins is formulated with a suitable adjuvant and administered by injection to human volunteers, accord¬ ing to known methods for producing human antisera. Antibody response to the injected proteins is monitored, during a several-week period following immunization, by periodic serum sampling to detect the presence of anti-HEV serum antibodies, using an immunoassay as described herein. The antiseru from immunized individuals may be administered as a pre-exposure prophylactic measure for individuals who are at risk of contracting infection. The antiserum is also useful in treating an individual post- exposure, analogous to the use of high titer antiserum against hepatitis B virus for post-exposure prophylaxis. For both in vivo use of antibodies to HEV virus-like particles and proteins and anti-idiotype antibodies and diagnostic use, it may be preferable to use monoclonal antibodies. Monoclonal anti-virus particle antibodies or anti-idiotype antibodies can be produced as follows. The spleen or lymphocytes from an immunized animal are removed and immortalized or used to prepare hybridomas by methods known to those skilled in the art. (Goding, J.W. 1983. Monoclonal Antibodies: Principles and Practice, Pladermic Press, Inc., NY, NY, pp. 56-97). To produce a human-human hybridoma, a human lymphocyte donor is selected. A donor known to be infected with HEV (where infection has been shown for example by the presence of anti-virus antibodies in the blood or by virus culture) may serve as a suitable lymphocyte donor. Lymphocytes can be isolated from a peripheral blood sample or spleen cells may be used if the donor is subject to splenectomy. Epstein-Barr virus (EBV) can be used to immortalize human lymphocytes or a human fusion partner can be used to produce human-human hybridomas. Primary .in vitro immunization with peptides can also be used in the generation of human monoclonal antibodies. Antibodies secreted by the immortalized cells are screened to determine the clones that secrete antibodies of the desired specificity. For monoclonal anti-virus particle antibodies, the antibodies must bind to HEV virus particles. For monoclonal anti-idiotype antibodies, the antibodies must bind to anti-virus particle antibodies. Cells producing antibodies of the desired specificity are selected. The above described antibodies and antigen binding fragments thereof may be supplied in kit form alone, or as a pharmaceutical composition for in vivo use. The antibodies may be used for therapeutic uses, diagnostic use in immunoassays or as an immunoaffinity agent to purify ORF proteins as described herein. Material The materials used in the following Examples were as follows: Primates . Chimpanzee (Chimp) (Pan troglodytes) . Old world monkeys: cynomolgus monkeys (Cyno) (Macaca fascicularis) , rhesus monkeys (Rhesus) (M. mulatta) , pigtail monkeys (PT) (M. nemestrina) , and African green monkeys (AGM) (Cercopithecus aethiops) . New World monkeys: mustached tamarins (Tarn) (Saguinus mystax) , squirrel monkeys (SQM) (Saimiri sciureus) and owl monkeys (OWL) (Aotus trivigatus) . Primates were housed singly under conditions of biohazard containment. The housing, maintenance and care of the animals met or exceeded all requirements for primate husbandry. Most animals were inoculated intravenously with HEV, strain SAR-55 contained in 0.5 ml of stool suspension diluted in fetal calf serum as described in Tsarev, S.A. et al. (1992), Proc. Natl. Acad. Sci USA. 89:559-563; and Tsarev, S.A. et al. (1992), J. Infect. Pis, (submitted). Chimp-1313 and 1310 were inoculated with a pool of stools collected from 7 Pakistani hepatitis E patients. Serum samples were collected approximately twice a week before and after inoculation. Levels of the liver enzymes serum alanine amino transferase (ALT) , isocitrate dehydrogenase (ICD) , and gamma glutamyl transferase (GGT) were assayed with commercially available tests (Medpath Inc. , Rockville, MD) . Serologic tests were performed as described above. EXAMPLE 1 Identification of the DNA Sequence of the Genome of HEV Strain SAR-55. Preparation of Virus RNA Template for PCR . Bile from an HEV-infected cynomolgus monkey (10 μl) , 20% (wt/vol) SDS (to a final concentration of 1%) , proteinase K (10 mg/ml; to a final concentration of 1 mg/ml) , 1 μl of tRNA (10 mg/ml), and 3 μl of 0.5 M EDTA were mixed in a final volume of 250 μl and incubated for 30 min. at 55°C. Total nucleic acids were extracted from bile twice with phenol/chloroform, 1:1 (vol/vol) , at 65°C and once with chloroform, then precipitated by ethanol, washed with 95% ethanol, and used for RT-PCR. RT-PCR amplification of HEV RNA from feces and especially from sera was more efficient when RNA was more extensively purified. Serum (100 μl) or a 10% fecal suspension (200 μl) was treated as above with proteinase K. After a 30-min incubation, 300 μl of CHAOS buffer (4.2 M guanidine thiocyanate/0.5 N- lauroylsarocosine/0.025 M Tris-HCL, Ph 8.0) was added. Nucleic acids were extracted twice with phenol/chloroform at 65°C followed by chloroform extraction at room temperature. Then 7.5 M ammonium acetate (225 μl) was added to the upper phase and nucleic acids were precipitated with 0.68 ml of 2-propanol. The pellet was dissolved in 300 ul CHAOS buffer and 100 ul of H 2 0 was added. Chloroform extraction and 2-propanol precipitation were repeated. Nucleic acids were dissolved in water, precipitated with ethanol, washed with 95% ethanol, and used for RT-PCR. Prijπers. Ninety-four primers, 21-40 nucleotides (nt) long, and complementary to plus or minus strands of the genome of a strain of HEV from Burma (BUR-121) (Tarn, A.W. et al. (1991), Virology. 185:120-131) or the SAR-55 genome were synthesized using an Applied Biosystems model 391 DNA synthesizer. The sequences of these 94 primers are shown below starting with SEQ. ID NO. 5 and continuing to SEQ. ID NO. 98: HEV Primer List 211 B CATTTCACTGAGTCAGTGAA GZ (SEQ. ID. NO. 23) 202 B TAATTATAACACCACTGCTA G (SEQ. ID. NO. 24) R 201 B GATTGCAATACCCTTATCCT G (SEQ. ID. NO. 25) 200 S ATTAAACCTGTATAGGGCAG AAC (SEQ. ID. NO. 26) 199 S AAGTTCGATAGCCAGATTTG C (SEQ. ID. NO. 27) R 198 S TCATGTTGGTTGTCATAATC C (SEQ. ID. NO. 28) 193 B GATGACGCACTTCTCAGTGT G (SEQ. ID. NO. 29) R 192 B 1 AGAACAACGAACGGAGAAC (SEQ. ID. NO. 30) D 191 B 1 AGATCCCAGCCATCGACTTT G (SEQ. ID. NO. 31) R 190 S TAGTAGTGTAGGTGGAAATA G (SEQ. ID. NO. 32) 189 B GTGTGGTTATTCAGGATTAT G (SEQ. ID. NO. 33) 188 B ACTCTGTGACCTTGGTTAAT G (SEQ. ID. NO. 34) R 187 S AACTCAAGTTCGAGGGCAAA G (SEQ. ID. NO. 35) D 186 S CGCTTACCCTGTTTAACCTT G (SEQ. ID. NO. 36) D 185 B 2,3 ATCCCCTATATTCATCCAAC CAAC (SEQ. ID. NO. 37) D 184 S 2,3 CTCCTCATGTTTCTGCCTAT G (SEQ. ID. NO. 38) R 181 S GCCAGAACGAAATGGAGATA GC (SEQ. ID. NO. 39) R 180 B CTCAGACATAAAACCTAAGT C (SEQ. ID. NO. 40) D 179 S TGCCCTATACAGGTTTAATC G (SEQ. ID. NO. 41) D 178 B 1 ACCGGCATATACCAGGTGC (SEQ. ID. NO. 42) D 177 B 2 ACATGGCTCACTCGTAAATT C (SEQ. ID. NO. 43) R 174 B AACATTAGACGCGTTAACGA G (SEQ. ID. NO. 44) ATAAAGAACCAGG (EcoRI) (SEQ. ID. NO. 62) 111 B 2 GCGCTGAATTCGGATCACAA GCTCAGAGGCTATGCC (ECORI) (SEQ. ID. NO. 63) (SEQ. ID. NO. 64) (SEQ. ID. NO. 65) (SEQ. ID. NO. 66) (SEQ. ID. NO. 67) (SEQ. ID. NO. 68) GGCTGAGATCTGGTTCGGGT CGCCAAGAAGGTG (Bgl II) (SEQ. ID. NO. 69) TACAGATCTATACAACTTAA CAGTCGG (Bgl II) (SEQ. ID. NO. 70) GCGGCAGATCTCACCGACAC CATTAGTAC (Bgl II) (SEQ. ID. NO. 71) CCGTCGGATCCCAGGGGCTG CTGTCCTG (Bam HI) (SEQ. ID. NO. 72) AAAGGAATTCAAGACCAGAG GTAGCCTCCTC (EcoRI) (SEQ. ID. NO. 73) GTTGATATGAATTCAATAAC CTCGACGG (SEQ. ID. NO. 74) TTTGGATCCTCAGGGAGCGC GGAACGCAGAAATGAG (BamHI) (SEQ. ID. NO. 75) TCACTCGTGAATTCCTATAC TAATAC (ECORI) (SEQ. ID. NO. 76) TTTGGATCCTCAGGGAGCGC GGAACGCAGAAATG (BamHI) (SEQ. ID. NO. 77) TGATAGAGCGGGACTTGCCG GATCC (BamHI) (SEQ. ID. NO. 78) TTGCATTAGGTTAATGAGGA TCTC (SEQ. ID. NO. 79) ACCTGCTTCCTTCAGCCTGC AGAAG (SEQ. ID. NO. 80) GCGGTGGATCCGCTCCCAGG CGTCAAAAC (BamHI) (SEQ. ID. NO. 81) GGGCGGATCGAATTCGAGAC CCTTCTTGG (EcoRI) (SEQ. ID. NO. 82) AGGATGGATCCATAAGTTAC CGATCAG (BamHI) (SEQ. ID. NO. 83) GGCTGGAATTCCTCTGAGGA CGCCCTCAC (EcoRI) (SEQ. ID. NO. 84) GCCGAAGATCTATCGGACAT AGACCTC (Bgl II) (SEQ. ID. NO. 85) CAGACGACGGATCCCCTTGG ATATAGCCTG (BamHI) (SEQ. ID. NO. 86) GGCCGAATTCAGGCAGACCA CATATGTGGTCGATGCCATG (ECORI) - (SEQ. ID. NO. 87) GCAGGTGTGCCTGGATCCGG CAAGT (BamHI) (SEQ. ID. NO. 88) GTTAGAATTCCGGCCCAGCT GTGGTAGGTC (EcoRI) (SEQ. ID. NO. 89) The abbreviations to the left of the sequences represent the following: R and D refer to reverse and forward primers, respectively; B and S refer to sequences derived from the Burma-121 Strain of Hepatitis E and the SAR-55 Strain of Hepatitis E, respectively; 5'NC and 3'NC refer to 5 prime and 3 prime non-coding regions of the HEV genome, respectively; and 1, 2 and 3 refer to sequence derived from open reading frames 1, 2 or 3, respectively. The symbol () to the right of some sequences shown indicates insertion of an artificial restriction site into these sequences. For cloning of PCR fragments, EcoRI, BajnHI, or Bglll restriction sites preceded by 3-7 nt were added to the 5' end of primers. RT-PCR . The usual 100-μl RT-PCR mixture contained template, 10 mM Tris-HCL (ph 8.4), 50 mM KC1, 2.5 mM MgCl 2 , all four dNTPs (each at 0.2 mM) , 50 pmol of direct primer, 50 pmol of reverse primer, 40 units of RNasin (Promega) , 16 units of avian myeloblastosis virus reverse transcriptase (Promega) , 4 units of AmpliTaq (Cetus) , under 100 μl of light mineral oil. The mixture was incubated 1 h at 42°C and then amplified by 35 PCR cycles; 1 min at 94°C, 1 min at 45°C, and 1 min at 72°C. The PCR products were analyzed on 1% agarose gels. Cloning of PCR Fragments . PCR fragments containing restriction sites at the ends were digested with EcoRI and BamHi or EcoRI and BglII restriction enzymes and cloned in EcoRI /BamHI-digested pBR322 or pGEM-3Z (Promega) . Alternatively, PCR fragments were cloned into pCRlOOO (Invitrogen) using the TA cloning kit (Invitrogen) . Sequencing of PCR Fragments and Plasmids . PCR fragments were excised from 1% agarose gels and purified by Geneclean (Bio 101, La Jolla, CA) . Double-stranded PCR fragments were sequenced by using Sequenase (United States Biochemical) as described in Winship, P.R. (1984), Nucleic Acids Rev.. 17:1266. Double-stranded plasmids purified through CsCl gradients were sequenced with a Sequenase kit (United States Biochemical) . Computer Analysis of Sequences . Nucleotide sequences of HEV strains were compared using the Genetics Computer Group (Madison, WI) software package (Devereaux, J. et al. (1984), Nucleic Acids Rev.. 12:387-395, version 7.5, on a VAX 8650 computer (at the National Cancer Institute, Frederick, MD) ) . EXAMPLE 2 Construction of a Recombinant Expression Vector. P63-2 . A plasmid containing the complete ORF-2 of the genome of HEV strain SAR-55, Tsarev, S.A. et al. (1992) , Proc. Natl. Acad. Sci. USA, 89:559-563), was used to obtain a restriction fragment Nrul-Bglll. Nrul cut the HEV cDNA five nucleotides upstream of the ATG initiation codon of ORF-2. An artificial Bgl II site previously had been placed at the 3' end of HEV genome just before the poly A sequence (Tsarev, S.A. et al. (1992) , Proc. Natl. Acad. Sci. USA. 89:559-563). To insert this fragment into pBlueBac-Transfer vector (Invitrogen) a synthetic polylinker was introduced into the unique Nhel site in the vector. This polylinker contained Bin I and Bgl II sites which are absent in both HEV cDNA and pBlueBac sequences. The Nrul-Bglll ORF-2 fragment was inserted in Bin I-Bglll pBlueBac using an adapter as shown in Fig. 1. EXAMPLE 3 Expression of P63-2 in SF9 Insect Cells . p63-2 and AcMNPV baculovirus DNA (Invitrogen) were cotransfected into SF9 cells (Invitrogen) by the Ca precipitation method according to the Invitrogen protocol - By following this protocol; the AcMNPV baculovirus DNA can produce a live intact baculovirus which can package p63-2 to form a recombinant baculovirus. This recombinant baculovirus was plaque-purified 4 times. The resulting recombinant baculovirus 63-2-IV-2 was used to infect SF9 cells. SDS-PAGE and Western blot . Insect cells were resuspended in loading buffer (50 mM Tris-HCl, pH 6.8, 100 mM DTT, 2% SDS, 0.1% bromphenol blue and 10% glycerol) and SDS-polyacrylamide gel electrophoresis was performed as described, Laem li, U.K. (1970), Nature, 227:680. Gels were stained with coomassie blue or proteins were electroblotted onto BA-85 nitrocellulose filters (Schleicher & Schuell) . After transfer, nitrocellulose membranes were blocked in PBS containing 10% fetal calf serum and 0.5% gelatin. As a primary antibody, hyperimmune serum of chimpanzee-1313 diluted 1:1000 was used. As a secondary antibody, phosphatase-labeled affinity-purified goat antibody to human IgG (Kirkegaard & ° Perry Laboratories, Inc.) diluted 1:2000 was used. Filters were developed in Western blue stabilized substrate for alkaline phosphatase (Promega) . All incuba¬ tions were performed in blocking solution, and washes were ^ with PBS with 0.05% Tween-20 (Sigma). Expression of HEV ORF-2 . The major protein synthesized in SF9 cells infected with recombinant baculo¬ virus 63-2-IV-2 was a protein with an apparent molecular 0 weight of 74 KD (Fig. 2A) . This size is a little larger than that predicted for the entire ORF-2 (71 KD) . The size difference could be due to glycosylation of the protein since there is at least one potential site of 5 glycosylation (Asn-Leu-Ser) in the N-terminal part. This protein was not detected in noninfected cells or in cells infected with wild-type nonrecombinant baculovirus. In 0 the latter case, the major protein detected was a polyhedron protein. When the same lysates were analyzed by Western blot with serum of chimp-1313 (hyperimmunized with HEV) , only proteins in the recombinant cell lysate 5 reacted and the major band was again represented by a 74 KD protein (Fig. 2B) . Minor bands were also present in the Western blot. Some of them had molecular weights higher than 74 KD, which could be due to different extents of glycosylation and some had lower molecular weights, which could reflect processing and/or degradation. Serum \ drawn from Chimp-1313 prior to inoculation with HEV did not react with any of the proteins by Western blot. EXAMPLE 4 Immunoelectron Microscopy of Recombinant Infected SF9 Cells . 5xl0 6 recombinant infected SF9 cells were sonicated in CsCl (1.30 g/ml) containing 10 mM Tris-HCl, pH 7.4, 0.3% sarcosyl and centrifuged 68 h, at 40,000 rpm (SW60Ti) . 50 ul of the fraction, which had the highest ELISA response and a buoyant density of 1.30 g/ml was diluted in 1 ml PBS and 5 ul of chimp-1313 hyperimmune serum was added. The hyperimmune serum was prepared by rechallenging a previously infected chimp with a second strain of hepatitis E (Mexican HEV) . Samples were incubated 1 h at room temperature and then overnight at 4 ° C. Immune complexes were precipitated using a SW60Ti rotor at 30,000 rpm, 4 ° C, 2 h. Pellets were resuspended in distilled water, negatively stained with 3% PTA. placed on carbon grids and examined at a magnification of 40,000 in an electron microscope EM-10, Carl Zeiss, Oberkochen, Germany. Detection of VLPs . Cell lysates from insect cells infected with wild-type or recombinant baculovirus 63-2- IV-2 were fractionated by CsCl density centrifugation. When fractions of the CsCl gradient from the recombinant infected insect cells were incubated with Chimp-1313 hyperimmune serum, two kinds of virus-like particles (VLP) covered with antibody were observed in the fraction with buoyant density of 1.30 g/ml: first (Fig. 3A) , antibody covered individual particles that had a size (30 nm) and morphological structure suggestive of HEV, second (Fig. 3B) , antibody-coated aggregates of particles smaller than HEV (about 20 nm) but which otherwise resembled HEV. Direct EM showed the presence of a very heterogenous population of objects including some of 30 and 20 nm in diameter respectively, which looked like virus particles but, in the absence of bound antibody, could not be confirmed as HEV. A number of IEM experiments suggested that at least some of the protein(s) synthesized from the ORF-2 region of the HEV genome, had assembled into a particulate structure. It was observed that insect cells at a later stage of infection, when the proportion of smaller proteins was higher, consistently gave better results in ELISA. Therefore, unfractionated lysates of recombinant insect cells from a later stage of infection were used as antigen in ELISA in subsequent tests. EXAMPLE 5 Detection by ELISA Based on Antigen from Insect Cells Expressing Complete ORF-2 of Anti-HEV Following Infection with Different Strains of HEV. 5x10° SF9 cells infected with 63-2-IV-2 virus were resuspended in 1 ml of 10 mM Tris-HCl, pH 7.5, 0.15M NaCl then were frozen and thawed 3 times. 10 ul of this suspension was dissolved in 10 ml of carbonate buffer (pH 9.6) and used to cover one flexible microtiter assay plate (Falcon). Serum samples were diluted 1:20, 1:400 and 1:8000, or 1:100, 1:1000 and 1:10000. The same blocking and washing solutions as described for the Western blot were used in ELISA. As a secondary antibody, peroxidase- conjugated goat IgG fraction to human IgG or horse radish peroxidase-labelled goat anti-Old or anti-New World monkey immunoglobulin was used. The results were determined by measuring the optical density (O.D.) at 405 nm. To determine if insect cell-derived antigen repre¬ senting a Pakistani strain of HEV could detect anti-HEV antibody in cynomolgus monkeys infected with the Mexican strain of HEV, 3 monkeys were*examined (Fig. 4). Two monkeys cyno-80A82 and cyno-9A97, were infected with feces containing the Mexico '86 HEV strain (Ticehurst, J. et al. (1992), J. Infect. Pis.. 165:835-845) and the third monkey cyno-83 was infected with a second passage of the same strain. As a control, serum samples from cyno-374, infected with the Pakistani HEV strain SAR-55, were tested in the same experiment. All 3 monkeys infected with the Mexican strain seroconverted to anti-HEV. Animals from the first passage seroconverted by week 15 and from the second passage by week 5. Interestingly, the highest anti-HEV titer among the 4 animals, was found in cyno-83, inoculated with the second passage of the Mexican strain. Cynos inoculated with the first passage of the Mexican strain developed the lowest titers while those inoculated with the first passage of the Pakistani strain developed intermediate titers. EXAMPLE 6 Specificity of Anti-HEV ELISA Based on Antigen from Insect Cells Expressing Complete ORF-2. To estimate if the ELISA described here specifically detected anti-HEV to the exclusion of any other type of hepatitis related antibody, serum samples of chimps were analyzed, in sets of four, infected with the other known hepatitis viruses (Garci, P. et al. (1992) , J. Infect. Pis.. 165:1006-1011; Farci, P. et al. (1992), Science (in press); Ponzetto, A. et al. (1987) J Infect. Pis.. 155: 72-77; Rizzetto; m.et al. (1981) Hepatology 1: 567-574; reference for chimps - 1413, 1373, 1442, 1551 (HAV) ; and for chimps - 982, 1442, 1420, 1410 (HBV) ; is unpublished data from Purcell et al) (Table 1) . Samples of pre- inoculation and 5 week and 15 week post-inoculation sera were analyzed in HEV ELISA at serum dilutions of 1:100, 1:1000 and 1:10000. None of the sera from animals infected with HAV, HBV, HCV and HDV reacted in the ELISA for HEV antibody, but all 4 chimps inoculated with HEV developed the IgM and IgG classes of anti-HEV. Table 1. Serological assay of anti-HEV antibody in chimpanzees infected with different hepatitis viruses (Hepatitis A, B, C, P, E) chimp inocu¬ week of preserum weeks post-inoculation lated serocon- virus version 15 20/25 for ino¬ culated IgG IgM IgG IgM IgG IgM IgG IgM virus Chimp- 1413 HAV 5 Chimp- 1373 HAV 7 Chimp- 1442 HAV 5 Chimp- 1451 HAV 5 Chimp- 982 HBV 3 Chimp- 1442 HBV 7 Chimp- 1420 HBV 9 Chimp- 1410 HBV 5 Chimp- 51 HCV 10 Chimp- 502 HCV 12 Chimp- 105 HCV 28 Chimp- 793 HCV 13 Chimp- 904 HPV 8 Chi p- 814 HPV 7 Chimp- 800 HPV 10 Chimp- 29 HPV 10 Chimp- 1313 HEV 5 1:10000 1:100 1:1000 Chimp- 1310 HEV 5 1:10000 1:100 1:10000 Chimp- 1374 HEV 3 1:8000 1:8000 Chimp- 1375 HEV 3 1:8000 1:400 1:400 Chimp- 1313 HEVlst 0 ** 5 1:10000 1:1000 1:1000 Chimp- 1313 HEV2nd°** 0.5 1:100 - 1:10000 - 1:10000 * Chimp-1374 was positive for IgM anti-HEV three and four weeks post-inoculation (see Fig.5) ** Chimp-1313 was inoculated with HEV twice. 1st inoculation with pooled samples of 7 EXAMPLE 7 Determination of the Host Range of the SAR-55 Strain of HEV in Non-Human Primates . Pifferent primate species were inoculated with a standard stool suspension of HEV and serial serum samples were collected to monitor for infection. Serum ALT levels were determined as an indicator of hepatitis while seroconversion was defined by detection of anti-HEV. Both rhesus monkeys inoculated with HEV (Table 2) showed very prominent peaks of ALT activity as well as seroconversion. The first sign of increased ALT activity was observed on day 14 for both animals, and definitive seroconversion occurred on day 21. The maximum titer of anti-HEV was achieved on day 29. Table 2. Biochemical and serological profiles of HEV infection in 8 primate species e 'Bimodal or trimodal elevation of ALT. no = no ALT elevation or anti-HEV antibody detected, Both African green monkeys used in this study (Table 2) developed increased ALT activity and anti-HEV. Although AGM-230 died seven weeks post-inoculation, signs of infection were observed prior to that time. AGM-74 showed a bimodal increase in ALT activity as has been reported for other species (Tsarev, S.A. et al. (1992), J. Infect. Pis, (in press)). Seroconversion for AGM-74 and AGM-230 was first observed on days 27 and 21, respectively. Although both inoculated pigtail macaques demon- strated a slight increase in ALT activity these increases were not as prominent as in the case of the animals described previously. However, both monkeys seroconverted on day 21 and the anti-HEV titers were equivalent to those of the chimps and other Old World monkeys. Neither ta arin inoculated in this study showed any rise in ALT activity or seroconversion to anti-HEV (Table 2) . The squirrel monkeys responded with significantly lower levels of anti-HEV than chimps or Old World monkeys (Table 2) . The time of seroconversion was also delayed as compared with those other animals. SQM-868 seroconverted on day 41, and SQM-869 seroconverted on day 35. The anti- HEV titer was not higher than 1:400 at any time during more than three months of monitoring and clearly was waning in both animals after reaching a peak value on days 47-54. However, the increases in ALT activity were rather prominent in both animals. The owl monkeys responded to HEV infection approximately as well as the Old World monkey species (Table 2) . Both OWMs seroconverted on day 21 and by day 28 the anti-HEV titer had reached a value of 1:8000. ALT activity peaked on day 35 in OWM-924, but not until day 91 in OWM-925. EXAMPLE 8 Detection of IaM and IgG Anti-HEV in Chimps . In both chimps, the serum ALT levels increased about 4 weeks post-inoculation (Table 2, Fig. 5). Both chimps seroconverted at the time of ALT enzyme elevation or earlier (Fig. 5A, 5C) . Levels of IgM anti-HEV also were determined for the chimps. In chimp-1374, the titer of IgM anti-HEV (Fig 5B) was not as high as the IgG titer (Fig 5A) and waned over two weeks. Although both IgG and IgM antibodies were first detected for this animal on day 20, the titer of IgM anti-HEV was the highest while the titer of IgG was the lowest on that day, but then rose and stayed approximately at the same level for more than three months. In chimp-1375, only IgM anti-HEV was detected on day 20 (Fig. 5D) . The titer was higher than in chimp-1374 and IgM anti-HEV was detected during the entire period of monitoring. IgG anti-HEV was first observed in this animal on day 27 (Fig. 5C) and remained at approximately the same level throughout the experiment. EXAMPLE 9 Comparison of ELISA Based on Complete ORF-2 Protein Expressed in Insect Cells With That Based on Fragments of Structural Proteins Expressed in E. coli . To estimate if expression of the complete ORF-2 region of the HEV genome in eukaryotic cells had any advantage over expression of fragments of structural proteins in E. coli , we used the former antigen in ELISA to retest cynomolgus monkey sera that had been analyzed earlier (Tsarev, S.A. et al. (1992) , Proc. Natl. Acad. Sci USA, 89:559-563; and Tsarev, S.A. et al. (1992) J. Infect. Pis, (submitted)), using the antigen fragments expressed in bacteria (Table 3) . Table 3. Comparison of ELISA based on antigen from insect cells expressing complete ORF-2 with that based on antigen from E.coli expressing fragments of structural proteins Cyno # aannttiiggeenn ddeerriivveedd ffrroomm antigen derived from bacterial cells insect cells (Portion of ORF-2) * (Complete ORF-2) day anti- HEV first detected Cyno-376 28 Cyno-369 54 Cyno-374 19 Cyno-375 26 Cyno-379 21 Cyno-381 28 "The sera were also tested with less sensitive ORF-3 antigen Tsarev, S.A. et al. (1992) , J. Infect. Pis, (in press) For 3 of the 6 monkeys examined by ELISA, the antigen expressed in insect cells detected seroconversion earlier than the antigen expressed in E. coli . Using the insect cell-derived antigen, we were able to detect anti-HEV antibody in sera from all six monkeys at the highest dilution tested (1:8000). With E. coli-cell derived antigen (Burma Strain) no information about anti-HEV titers were obtained, since all sera were tested only at a dilution of 1:100 (Tsarev, SA et al (1992) Proc. Nat. Acad. Sci. USA: 89:559-563; Tsarev et al. (1992) J^. Infect. Pis, (submitted) ) . In another study, hepatitis E virus, strain SAR-55 was serially diluted in 10-fold increments and the 10 "1 through 10' 5 dilutions were inoculated into pairs of cyno¬ molgus monkeys to titer the virus. The serum ALT levels were measured to determine hepatitis and serum antibody to HEV was determined by the ELISA method of the present invention (data in figures) or by Genelab's ELISA (data shown as positive (+) or negative (-) test at bottom of Figures 6 a-g) . All samples were tested under code. The ELISA method of the present invention detected seroconversion to IgG anti-HEV in all cynos inoculated and all dilutions of virus. In contrast, Genelab's results were strikingly variable, as summarized below. Table 4. ELISA of Pilution Present of Virus Genelab's ELISA Invention lO "1 did not test positive 10 "2 positive for both animals, limited duration positive 10 "3 negative for both animals positive Cyno 389: positive for IgM and IgG positive Cyno 383: negative positive 10- Cyno 386: negative positive Cyno 385: positive positive Since Cyno 385 (10 "5 ) was positive in ELISA tests both by Genelabs and the present invention, the 10 "4 (ten times more virus inoculated) and 10 '3 (100 times more virus inoculated) would also have been expected to be positive. The present invention scored them as positive in contrast to Genelab's ELISA test which missed both positives at 10 '3 and one at 10"* even though the ALT levels of Cyno 383 and 393 suggested active hepatitis. Therefore, the data support the advantages of the present ELISA method over the prior art methods of detecting antibodies to HEV. EXAMPLE 10 Use of the Complete ORF-2 Protein as a Vaccine . As previously described above, the recombinant ORF-2 protein is immunoreactive. Additionally, it has been shown to react with a variety of sera taken from different species of animals infected with different strains of HEV. This provides support for the use of this recombinant protein as a vaccine to protect against a variety of HEV strains. Mammals are immunized with purified or partially purified recombinant ORF-2 protein in an amount sufficient to stimulate the production of protective antibodies. The immunized animals challenged with the wild-type strain of HEV are protected. The contents of all citations, i.e. , journal articles, patents and the like, are incorporated herein by reference. It is understood that the examples and embodiments described herein are for illustrative purposes and that various modifications and changes in light thereof to persons skilled in the art are included within the spirit and purview of this application and scope of the appended claims. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANTS: Tsarev, Sergei A., Emerson, Suzanne U. , Purcell, Robert H. (ii) TITLE OF INVENTION: Recombinant Proteins Of A Pakistani Strain Of Hepatitis E And Their Use In Piagnostic Methods And Vaccines (iii) NUMBER OF SEQUENCES: 98 (iv) CORRESPONPENCE APPRESS: (A) APPRESSEE: MORGAN ' FINNEGAN (B) STREET: 345 PARK AVENUE (C) CITY: NEW YORK (P) STATE: NEW YORK (E) COUNTRY: USA (F) ZIP: 10154 (v) COMPUTER REAPABLE FORM: (A) MEPIUM TYPE: FLOPPY PISK (B) COMPUTER: IBM PC COMPATIBLE (C) OPERATING SYSTEM: PC-POS/MS-POS (P) SOFTWARE: WORPPERFECT 5.1 (vi) CURRENT APPLICATION PATA: (A) APPLICATION NUMBER: 07/947,263 (B) FILING DATE: 18-SEP-1992 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: Bork, Richard, W. (B) REGISTRATION NUMBER: 36,459 (C) REFERENCE/DOCKET NUMBER: 2026-4032 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 758-4800 (B) TELEFAX: (212) 751-6849 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1693 amino acid residues (B) TYPE: amino acid (C) STRANDEDNESS: unknown (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: Met Glu Ala His Gin Phe He Lys Ala Pro Gly He Thr Thr Ala 1 5 10 15 He Glu Gin Ala Ala Leu Ala Ala Ala Asn Ser Ala Leu Ala Asn 20 25 30 Ala Val Val Val Arg Pro Phe Leu Ser His Gin Gin He Glu He 35 40 45 Leu He Asn Leu Met Gin Pro Arg Gin Leu Val Phe Arg Pro Glu 50 55 60 Val Phe Trp Asn His Pro He Gin Arg Val He His Asn Glu Leu 65 70 75 Glu Leu Tyr Cys Arg Ala Arg Ser Gly Arg Cys Leu Glu He Gly 80 85 90 Ala His Pro Arg Ser He Asn Asp Asn Pro Asn Val Val His Arg 95 100 105 Cys Phe Leu Arg Pro Ala Gly Arg Asp Val Gin Arg Trp Tyr Thr 110 115 120 Ala Pro Thr Arg Gly Pro Ala Ala Asn Cys Arg Arg Ser Ala Leu 125 130 135 Arg Gly Leu Pro Ala Ala Asp Arg Thr Tyr Cys Phe Asp Gly Phe 140 145 150 Ser Gly Cys Asn Phe Pro Ala Glu Thr Gly He Ala Leu Tyr Ser 155 160 165 Leu His Asp Met Ser Pro Ser Asp Val Ala Glu Ala Met Phe Arg 170 175 180 His Gly Met Thr Arg Leu Tyr Ala Ala Leu His Leu Pro Pro Glu 185 190 195 Gly Leu Glu Val Arg Tyr Val Ala Ala Gly Leu Asp His Arg Ala 620 625 630 Val Phe Ala Pro Gly Val Ser Pro Arg Ser Ala Pro Gly Glu Val 635 640 645 Thr Ala Phe Cys Ser Ala Leu Tyr Arg Phe Asn Arg Glu Ala Gin 650 655 660 Arg Leu Ser Leu Thr Gly Asn Phe Trp Phe His Pro Glu Gly Leu 665 670 675 Leu Gly Pro Phe Ala Pro Phe Ser Pro Gly His Val Trp Glu Ser 680 685 690 Ala Asn Pro Phe Cys Gly Glu Ser Thr Leu Tyr Thr Arg Thr Trp 695 700 705 Ser Glu Val Asp Ala Val Pro Ser Pro Ala Gin Pro Asp Leu Gly 710 715 720 Phe Thr Ser Glu Pro Ser He Pro Ser Arg Ala Ala Thr Pro Thr 725 730 735 Pro Ala Ala Pro Leu Pro Pro Pro Ala Pro Asp Pro Ser Pro Thr 740 745 750 Leu Ser Ala Pro Ala Arg Gly Glu Pro Ala Pro Gly Ala Thr Ala 755 760 765 Arg Ala Pro Ala He Thr His Gin Thr Ala Arg His Arg Arg Leu 770 775 780 Leu Phe Thr Tyr Pro Asp Gly Ser Lys Val Phe Ala Gly Ser Leu 785 790 795 Phe Glu Ser Thr Cys Thr Trp Leu Val Asn Ala Ser Asn Val Asp 800 805 810 His Arg Pro Gly Gly Gly Leu Cys His Ala Phe Tyr Gin Arg Tyr 815 820 825 Pro Ala Ser Phe Asp Ala Ala Ser Phe Val Met Arg Asp Gly Ala 830 835 840 Ala Ala Tyr Thr Leu Thr Pro Arg Pro He He His Ala Val Ala 845 850 855 Pro Asp Tyr Arg Leu Glu His Asn Pro Lys Arg Leu Glu Ala Ala 860 • 865 870 Tyr Arg Glu Thr Cys Ser Arg Leu Gly Thr Ala Ala Tyr Pro Leu 875 880 885 Leu Gly Thr Gly He Tyr Gin Val Pro He Gly Pro Ser Phe Asp 890 895 900 Ala Trp Glu Arg Asn His Arg Pro Gly Asp Glu Leu Tyr Leu Pro 905 910 915 Glu Leu Ala Ala Arg Trp Phe Glu Ala Asn Arg Pro Thr Cys Pro 920 925 930 Thr Leu Thr He Thr Glu Asp Val Ala Arg Thr Ala Asn Leu Ala 935 940 945 He Glu Leu Asp Ser Ala Thr Asp Val Gly Arg Ala Cys Ala Gly 950 955 960 Cys Arg Val Thr Pro Gly Val Val Gin Tyr Gin Phe Thr Ala Gly 965 970 975 Val Pro Gly Ser Gly Lys Ser Arg Ser He Thr Gin Ala Asp Val 980 985 990 Asp Val Val Val Val Pro Thr Arg Glu Leu Arg Asn Ala Trp Arg 995 1000 1005 Arg Arg Gly Phe Ala Ala Phe Thr Pro His Thr Ala Ala Arg Val 1010 1015 1020 Thr Gin Gly Arg Arg Val Val He Asp Glu Ala Pro Ser Leu Pro 1025 1030 1035 Pro His Leu Leu Leu Leu His Met Gin Arg Ala Ala Thr Val His 1040 1045 1050 Leu Leu Gly Asp Pro Asn Gin He Pro Ala He Asp Phe Glu His 1055 1060 1065 Ala Gly Leu Val Pro Ala He Arg Pro Asp Leu Ala Pro Thr Ser 1070 1075 1080 Trp Trp His Val Thr His Arg Cys Pro Ala Asp Val Cys Glu Leu 1085 1090 1095 He Arg Gly Ala Tyr Pro Met He Gin Thr Thr Ser Arg Val Leu 1100 1105 1110 Arg Ser Leu Phe Trp Gly Glu Pro Ala Val Gly Gin Lys Leu Val 1115 1120 1125 Phe Thr Gin Ala Ala Lys Ala Ala Asn Pro Gly Ser Val Thr Val 1130 1135 1140 His Glu Ala Gin Gly Ala Thr Tyr Thr Glu Thr Thr He He Ala 1145 1150 1155 Thr Ala Asp Ala Arg Gly Leu He Gin Ser Ser Arg Ala His Ala 1160 1165 1170 He Val Ala Leu Thr Arg His Thr Glu Lys Cys Val He He Asp 1175 • 1180 1185 Ala Pro Gly Leu Leu Arg Glu Val Gly He Ser Asp Ala He Val 1190 1195 1200 Asn Asn Phe Phe Leu Ala Gly Gly Glu He Gly His Gin Arg Pro 1205 1210 1215 Ser Val He Pro Arg Gly Asn Pro Asp Ala Asn Val Asp Thr Leu 1220 1225 1230 Ala Ala Phe Pro Pro Ser Cys Glu He Ser Ala Phe His Glu Leu 1235 1240 1245 Ala Glu Glu Leu Gly His Arg Pro Ala Pro Val Ala Ala Val Leu 1250 1255 1260 Pro Pro Cys Pro Glu Leu Glu Gin Gly Leu Leu Tyr Leu Pro Gin 1265 1270 1275 Glu Leu Thr Thr Cys Asp Ser Val Val Thr Phe Glu Leu Thr Asp 1280 1285 1290 He Val His Cys Arg Met Ala Ala Pro Ser Gin Arg Lys Ala Val 1295 1300 1305 Leu Ser Thr Leu Val Gly Arg Tyr Gly Arg Arg Thr Lys Leu Tyr 1310 1315 1320 Asn Ala Ser His Ser Asp Val Arg Asp Ser Leu Ala Arg Phe He 1325 1330 1335 Pro Ala He Gly Pro Val Gin Val Thr Thr Cys Glu Leu Tyr Glu 1340 1345 1350 Leu Glu Glu Ala Met Val Glu Lys Gly Gin Asp Gly Ser Ala Val 1355 1360 1365 Leu Glu Leu Asp Leu Cys Ser Arg Asp Val Ser Arg He Thr Phe 1370 1375 1380 Phe Gin Lys Asp Cys Asn Lys Phe Thr Thr Gly Glu Thr He Ala 1385 1390 1395 His Gly Lys Val Gly Gin Gly He Ser Ala Trp Ser Lys Thr Phe 1400 1405 1410 Cys Ala Leu Phe Gly Pro Trp Phe Arg Ala He Glu Lys Ala He 1415 1420 1425 Leu Ala Leu Leu Pro Gin Gly Val Phe Tyr Gly Asp Ala Phe Asp 1430 1435 1440 Asp Thr Val Phe Ser Ala Ala Val Ala Ala Ala Lys Ala Ser Met 1445 1450 1455 Val Phe Glu Asn Asp Phe Ser Glu Phe Asp Ser Thr Gin Asn Asn 1460 1465 1470 Phe Ser Leu Gly Leu Glu Cys Ala He Met Glu Glu Cys Gly Met 1475 1480 1485 Pro Gin Trp Leu He Arg Leu Tyr His Leu He Arg Ser Ala Trp 1490 • 1495 1500 He Leu Gin Ala Pro Lys Glu Ser Leu Arg Gly Phe Trp Lys Lys 1505 1510 1515 His Ser Gly Glu Pro Gly Thr Leu Leu Trp Asn Thr Val Trp Asn 1520 1525 1530 Met Ala Val He Thr His Cys Tyr Asp Phe Arg Asp Leu Gin Val 1535 1540 1545 Ala Ala Phe Lys Gly Asp Asp Ser He Val Leu Cys Ser Glu Tyr 1550 1555 1560 Arg Gin Ser Pro Gly Ala Ala Val Leu He Ala Gly Cys Gly Leu 1565 1570 1575 Lys Leu Lys Val Asp Phe Arg Pro He Gly Leu Tyr Ala Gly Val 1580 1585 1590 Val Val Ala Pro Gly Leu Gly Ala Leu Pro Asp Val Val Arg Phe 1595 1600 1605 Ala Gly Arg Leu Thr Glu Lys Asn Trp Gly Pro Gly Pro Glu Arg 1610 1615 1620 Ala Glu Gin Leu Arg Leu Ala Val Ser Asp Phe Leu Arg Lys Leu 1625 1630 1635 Thr Asn Val Ala Gin Met Cys Val Asp Val Val Ser Arg Val Tyr 1640 1645 1650 Gly Val Ser Pro Gly Leu Val His Asn Leu He Glu Met Leu Gin 1655 1660 1665 Ala Val Ala Asp Gly Lys Ala His Phe Thr Glu Ser Val Lys Pro 1670 1675 1680 Val Leu Asp Leu Thr Asn Ser He Leu Cys Arg Val Glu 1685 1690 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 660 amino acid residues (B) TYPE: amino acid (C) STRANDEPNESS: unknown (D) TOPOLOGY: unknown (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Arg Pro Arg Pro He Leu Leu Leu Leu Leu Met Phe Leu Pro 1 5 10 15 Met Leu Pro Ala Pro Pro Pro Gly Gin Pro Ser Gly Arg Arg Arg 20 25 30 Gly Arg Arg Ser Gly Gly Ser Gly Gly Gly Phe Trp Gly Asp Arg 35 40 45 Val Asp Ser Gin Pro Phe Ala He Pro Tyr He His Pro Thr Asn 50 * 55 60 Pro Phe Ala Pro Asp Val Thr Ala Ala Ala Gly Ala Gly Pro Arg 65 70 75 Val Arg Gin Pro Ala Arg Pro Leu Gly Ser Ala Trp Arg Asp Gin 80 85 90 Ala Gin Arg Pro Ala Ala Ala Ser Arg Arg Arg Pro Thr Thr Ala 95 100 105 Gly Ala Ala Pro Leu Thr Ala Val Ala Pro Ala His Asp Thr Pro 110 115 120 Pro Val Pro Asp Val Asp Ser Arg Gly Ala He Leu Arg Arg Gin 125 130 135 Tyr Asn Leu Ser Thr Ser Pro Leu Thr Ser Ser Val Ala Thr Gly 140 145 150 Thr Asn Leu Val Leu Tyr Ala Ala Pro Leu Ser Pro Leu Leu Pro 155 160 165 Leu Gin Asp Gly Thr Asn Thr His He Met Ala Thr Glu Ala Ser 170 175 180 Asn Tyr Ala Gin Tyr Arg Val Ala Arg Ala Thr He Arg Tyr Arg 185 190 195 Pro Leu Val Pro Asn Ala Val Gly Gly Tyr Ala He Ser He Ser 200 205 210 Phe Tyr Pro Gin Thr Thr Thr Thr Pro Thr Ser Val Asp Met Asn 215 220 225 Ser He Thr Ser Thr Asp Val Arg He Leu Val Gin Pro Gly He 230 235 240 Ala Ser Glu Leu Val He Pro Ser Glu Arg Leu His Tyr Arg Asn 245 250 255 Gin Gly Trp Arg Ser Val Glu Thr Ser Gly Val Ala Glu Glu Glu 260 265 270 Ala Thr Ser Gly Leu Val Met Leu Cys He His Gly Ser Pro Val 275 280 285 Asn Ser Tyr Thr Asn Thr Pro Tyr Thr Gly Ala Leu Gly Leu Leu 290 295 300 Asp Phe Ala Leu Glu Leu Glu Phe Arg Asn Leu Thr Pro Gly Asn 305 310 315 Thr Asn Thr Arg Val Ser Arg Tyr Ser Ser Thr Ala Arg His Arg 320 325 330 Leu Arg Arg Gly Ala Asp Gly Thr Ala Glu Leu Thr Thr Thr Ala 335 340 345 Ala Thr Arg Phe Met Lys Asp Leu Tyr Phe Thr Ser Thr Asn Gly 350 355 360 Val Gly Glu He Gly Arg Gly He Ala Leu Thr Leu Phe Asn Leu 365 ' 370 375 Ala Asp Thr Leu Leu Gly Gly Leu Pro Thr Glu Leu He Ser Ser 380 385 390 Ala Gly Gly Gin Leu Phe Tyr Ser Arg Pro Val Val Ser Ala Asn 395 400 405 Gly Glu Pro Thr Val Lys Leu Tyr Thr Ser Val Glu Asn Ala Gin 410 415 420 Gin Asp Lys Gly He Ala He Pro His Asp He Asp Leu Gly Glu 425 430 435 Ser Arg Val Val He Gin Asp Tyr Asp Asn Gin His Glu Gin Asp 440 445 450 Arg Pro Thr Pro Ser Pro Ala Pro Ser Arg Pro Phe Ser Val Leu 455 460 465 Arg Ala Asn Asp Val Leu Trp Leu Ser Leu Thr Ala Ala Glu Tyr 470 475 480 Asp Gin Ser Thr Tyr Gly Ser Ser Thr Gly Pro Val Tyr Val Ser 485 490 495 Asp Ser Val Thr Leu Val Asn Val Ala Thr Gly Ala Gin Ala Val 500 505 510 Ala Arg Ser Leu Asp Trp Thr Lys Val Thr Leu Asp Gly Arg Pro 515 520 525 Leu Ser Thr He Gin Gin Tyr Ser Lys Thr Phe Phe Val Leu Pro 530 535 540 Leu Arg Gly Lys Leu Ser Phe Trp Glu Ala Gly Thr Thr Lys Ala 545 550 555 Gly Tyr Pro Tyr Asn Tyr Asn Thr Thr Ala Ser Asp Gin Leu Leu 560 565 570 Val Glu Asn Ala Ala Gly His Arg Val Ala He Ser Thr Tyr Thr 575 580 585 Thr Ser Leu Gly Ala Gly Pro Val Ser He Ser Ala Val Ala Val 590 595 600 Leu Ala Pro His Ser Val Leu Ala Leu Leu Glu Asp Thr Met Asp 605 610 615 Tyr Pro Ala Arg Ala His Thr Phe Asp Asp Phe Cys Pro Glu Cys 620 625 630 Arg Pro Leu Gly Leu Gin Gly Cys Ala Phe Gin Ser Thr Val Ala 635 640 645 Glu Leu Gin Arg Leu Lys Met Lys Val Gly Lys Thr Arg Glu Leu 650 655 660 2) INFORMATION FOR SEQ IP NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 123 amino acid residues (B) TYPE: amino acid (C) STRANPEPNESS: unknown (P) TOPOLOGY: unknown (xi) SEQUENCE PESCRIPTION: SEQ IP NO:3: Met Asn Asn Met Ser Phe Ala Ala Pro Met Gly Ser Arg Pro Cys 1 5 10 15 Ala Leu Gly Leu Phe Cys Cys Cys Ser Ser Cys Phe Cys Leu Cys 20 25 30 Cys Pro Arg His Arg Pro Val Ser Arg Leu Ala Ala Val Val Gly 35 40 45 Gly Ala Ala Ala Val Pro Ala Val Val Ser Gly Val Thr Gly Leu 50 55 60 He Leu Ser Pro Ser Gin Ser Pro He Phe He Gin Pro Thr Pro 65 70 75 Ser Pro Pro Met Ser Pro Leu Arg Pro Gly Leu Asp Leu Val Phe 80 85 90 Ala Asn Pro Pro Asp His Ser Ala Pro Leu Gly Val Thr Arg Pro 95 100 105 Ser Ala Pro Pro Leu Pro His Val Val Asp Leu Pro Gin Leu Gly 110 115 120 Pro Arg Arg (2) INFORMATION FOR SEQ IP NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7168 base pairs (B) TYPE: nucleic acid (C) STRANPEPNESS: single (P) TOPOLOGY: linear (xi) SEQUENCE PESCRIPTION: SEQ ID NO:4: AGGCAGACCA CATATGTGGT CGATGCCATG GAGGCCCATC AGTTTATCAA 50 GGCTCCTGGC ATCACTACTG CTATTGAGCA GGCTGCTCTA GCAGCGGCCA 100 ACTCTGCCCT TGCGAATGCT GTGGTAGTTA GGCCTTTTCT CTCTCACCAG 150 CAGATTGAGA TCCTTATTAA CCTAATGCAA CCTCGCCAGC TTGTTTTCCG ( 200 CCCCGAGGTT TTCTGGAACC ATCCCATCCA GCGTGTTATC CATAATGAGC 250 TGGAGCTTTA CTGTCGCGCC CGCTCCGGCC GCTGCCTCGA AATTGGTGCC 300 CACCCCCGCT CAATAAATGA CAATCCTAAT GTGGTCCACC GTTGCTTCCT 350 CCGTCCTGCC GGGCGTGATG TTCAGCGTTG GTATACTGCC CCTACCCGCG 400 GGCCGGCTGC TAATTGCCGG CGTTCCGCGC TGCGCGGGCT CCCCGCTGCT 450 GACCGCACTT ACTGCTTCGA CGGGTTTTCT GGCTGTAACT TTCCCGCCGA 500 GACGGGCATC GCCCTCTATT CTCTCCATGA TATGTCACCA TCTGATGTCG 550 CCGAGGCTAT GTTCCGCCAT GGTATGACGC GGCTTTACGC TGCCCTCCAC 600 CTCCCGCCTG AGGTCCTGTT GCCCCCTGGC ACATACCGCA CCGCGTCGTA 650 CTTGCTGATC CATGACGGCA GGCGCGTTGT GGTGACGTAT GAGGGTGACA 700 CTAGTGCTGG TTATAACCAC GATGTTTCCA ACCTGCGCTC CTGGATTAGA 750 ACCACTAAGG TTACCGGAGA CCACCCTCTC GTCATCGAGC GGGTTAGGGC 800 CATTGGCTGC CACTTTGTCC TTTTACTCAC GGCTGCTCCG GAGCCATCAC 850 CTATGCCCTA TGTCCCTTAC CCCCGGTCTA CCGAGGTCTA TGTCCGATCG 900 ATCTTCGGCC CGGGTGGCAC CCCCTCCCTA TTTCCAACCT CATGCTCCAC 950 CAAGTCGACC TTCCATGCTG TCCCTGCCCA TATCTGGGAC CGTCTCATGT 1000 TGTTCGGGGC CACCCTAGAT GACCAAGCCT TTTGCTGCTC CCGCCTAATG 1050 ACTTACCTCC GCGGCATTAG CTACAAGGTT ACTGTGGGCA CCCTTGTTGC 1100 CAATGAAGGC TGGAACGCCT CTGAGGACGC TCTTACAGCT GTCATCACTG 1150 CCGCCTACCT TACCATCTGC CACCAGCGGT ACCTCCGCAC TCAGGCTATA 1200 TCTAAGGGGA TGCGTCGCCT GGAGCGGGAG CATGCTCAGA AGTTTATAAC 1250 ACGCCTCTAC AGTTGGCTCT TTGAGAAGTC CGGCCGTGAT TATATCCCCG 1300 GCCGTCAGTT GGAGTTCTAC GCTCAGTGTA GGCGCTGGCT CTCGGCCGGC 1350 TTTCATCTTG ACCCACGGGT GTTGGTTTTT GATGAGTCGG CCCCCTGCCA 1400 CTGTAGGACT GCGATTCGTA AGGCGGTCTC AAAGTTTTGC TGCTTTATGA 1450 AGTGGCTGGG CCAGGAGTGC ACCTGTTTTC TACAACCTGC AGAAGGCGTC 1500 GTTGGCGACC AGGGCCATGA CAACGAGGCC TATGAGGGGT CTGATGTTGA 1550 CCCTGCTGAA TCCGCTATTA GTGACATATC TGGGTCCTAC GTAGTCCCTG 1600 GCACTGCCCT CCAACCGCTT TACCAAGCCC TTGACCTCCC CGCTGAGATT 1650 GTGGCTCGTG CAGGCCGGCT GACCGCCACA GTAAAGGTCT CCCAGGTCGA 1700 CGGGCGGATC GATTGTGAGA CCCTTCTCGG TAATAAAACC TTCCGCACGT 1750 CGTTTGTTGA CGGGGCGGTT TTAGAGACTA ATGGCCCAGA GCGCCACAAT 1800 CTCTCTTTTG ATGCCAGTCA GAGCACTATG GCCGCCGGCC CTTTCAGTCT 1850 CACCTATGCC GCCTCTGCTG CTGGGCTGGA GGTGCGCTAT GTCGCCGCCG 1900 GGCTTGACCA CCGGGCGGTT TTTGCCCCCG GCGTTTCACC CCGGTCAGCC 1950 CCTGGCGAGG TCACCGCCTT CTGTTCTGCC CTATACAGGT TTAATCGCGA 2000 GGCCCAGCGC CTTTCGCTGA CCGGTAATTT TTGGTTCCAT CCTGAGGGGC 2050 TCCTTGGCCC CTTTGCCCCG TTTTCCCCCG GGCATGTTTG GGAGTCGGCT 2100 AATCCATTCT GTGGCGAGAG CACACTTTAC ACCCGCACTT GGTCGGAGGT 2150 TGATGCTGTT CCTAGTCCAG CCCAGCCCGA CTTAGGTTTT ACATCTGAGC 2200 CTTCTATACC TAGTAGGGCC GCCACACCTA CCCCGGCGGC CCCTCTACCC 2250 CCCCCTGCAC CGGATCCTTC CCCTACTCTC TCTGCTCCGG CGCGTGGTGA 2300 GCCGGCTCCT GGCGCTACCG CCAGGGCCCC AGCCATAACC CACCAGACGG 2350 CCCGGCATCG CCGCCTGCTC TTTACCTACC CGGATGGCTC TAAGGTGTTC 2400 GCCGGCTCGC TGTTTGAGTC GACATGTACC TGGCTCGTTA ACGCGTCTAA 2450 TGTTGACCAC CGCCCTGGCG GTGGGCTCTG TCATGCATTT TACCAGAGGT 2500 ACCCCGCCTC CTTTGATGCT GCCTCTTTTG TGATGCGCGA CGGCGCGGCC 2550 GCCTACACAT TAACCCCCCG GCCAATAATT CATGCCGTCG CTCCTGATTA 2600 TAGGTTGGAA CATAACCCAA AGAGGCTTGA GGCTGCCTAC CGGGAGACTT 2650 GCTCCCGCCT CGGTACCGCT GCATACCCAC TCCTCGGGAC CGGCATATAC 2700 CAGGTGCCGA TCGGTCCCAG TTTTGACGCC TGGGAGCGGA ATCACCGCCC 2750 CGGGGACGAG TTGTACCTTC CTGAGCTTGC TGCCAGATGG TTCGAGGCCA 2800 ATAGGCCGAC CTGCCCAACT CTCACTATAA CTGAGGATGT TGCGCGGACA 2850 GCAAATCTGG CTATCGAACT TGACTCAGCC ACAGACGTCG GCCGGGCCTG 2900 TGCCGGCTGT CGAGTCACCC CCGGCGTTGT GCAGTACCAG TTTACCGCAG 2950 GTGTGCCTGG ATCCGGCAAG TCCCGCTCTA TTACCCAAGC CGACGTGGAC 3000 GTTGTCGTGG TCCCGACCCG GGAGTTGCGT AATGCCTGGC GCCGCCGCGG 3050 CTTCGCTGCT TTCACCCCGC ACACTGCGGC TAGAGTCACC CAGGGGCGCC 3100 GGGTTGTCAT TGATGAGGCC CCGTCCCTTC CCCCTCATTT GCTGCTGCTC 3150 CACATGCAGC GGGCCGCCAC CGTCCACCTT CTTGGCGACC CGAATCAGAT 3200 CCCAGCCATC GATTTTGAGC ACGCCGGGCT CGTTCCCGCC ATCAGGCCCG 3250 ATTTGGCCCC CACCTCCTGG TGGCATGTTA CCCATCGCTG CCCTGCGGAT 3300 GTATGTGAGC TAATCCGCGG CGCATACCCT ATGATTCAGA CCACTAGTCG 3350 GGTCCTCCGG TCGTTGTTCT GGGGTGAGCC CGCCGTTGGG CAGAAGCTAG 3400 TGTTCACCCA GGCGGCTAAG GCCGCCAACC CCGGTTCAGT GACGGTCCAT 3450 GAGGCACAGG GCGCTACCTA CACAGAGACT ACCATCATTG CCACGGCAGA 3500 TGCTCGAGGC CTCATTCAGT CGTCCCGAGC TCATGCCATT GTTGCCTTGA 3550 CGCGCCACAC TGAGAAGTGC GTCATCATTG ACGCACCAGG CCTGCTTCGC 3600 GAGGTGGGCA TCTCCGATGC AATCGTTAAT AACTTTTTCC TTGCTGGTGG 3650 CGAAATTGGC CACCAGCGCC CATCTGTTAT CCCTCGCGGC AATCCTGACG 3700 CCAATGTTGA CACCTTGGCT GCCTTCCCGC CGTCTTGCCA GATTAGCGCC 3750 TTCCATCAGT TGGCTGAGGA GCTTGGCCAC AGACCTGCCC CTGTCGCGGC 3800 TGTTCTACCG CCCTGCCCTG AGCTTGAACA GGGCCTTCTC TACCTGCCCC 3850 AAGAACTCAC CACCTGTGAT AGTGTCGTAA CATTTGAATT AACAGATATT 3900 GTGCATTGTC GTATGGCCGC CCCGAGCCAG CGCAAGGCCG TGCTGTCCAC 3950 GCTCGTGGGC CGTTATGGCC GCCGCACAAA GCTCTACAAT GCCTCCCACT 4000 CTGATGTTCG CGACTCTCTC GCCCGTTTTA TCCCGGCCAT TGGCCCCGTA 4050 CAGGTTACAA CCTGTGAATT GTACGAGCTA GTGGAGGCCA TGGTCGAGAA 4100 GGGCCAGGAC GGCTCCGCCG TCCTTGAGCT CGACCTTTGT AGCCGCGACG 4150 TGTCCAGGAT CACCTTCTTC CAGAAAGATT GTAATAAATT CACCACGGGG 4200 GAGACCATCG CCCATGGTAA AGTGGGCCAG GGCATTTCGG CCTGGAGTAA 4250 GACCTTCTGT GCCCTTTTCG GCCCCTGGTT CCGTGCTATT GAGAAGGCTA 4300 TCCTGGCCCT GCTCCCTCAG GGTGTGTTTT ATGGGGATGC CTTTGATGAC 4350 ACCGTCTTCT CGGCGGCTGT GGCCGCAGCA AAGGCATCCA TGGTGTTCGA 4400 GAATGACTTT TCTGAGTTTG ATTCCACCCA GAATAATTTT TCCTTGGGCC 4450 TAGAGTGTGC TATTATGGAG GAGTGTGGGA TGCCGCAGTG GCTCATCCGC 4500 TTGTACCACC TTATAAGGTC TGCGTGGATT CTGCAGGCCC CGAAGGAGTC 4550 CCTGCGAGGG TTTTGGAAGA AACACTCCGG TGAGCCCGGC ACCCTTCTGT 4600 GGAATACTGT CTGGAACATG GCCGTTATCA CCCACTGTTA TGATTTCCGC 4650 GATCTGCAGG TGGCTGCCTT TAAAGGTGAT GATTCGATAG TGCTTTGCAG 4700 TGAGTACCGT CAGAGCCCAG GGGCTGCTGT CCTGATTGCT GGCTGTGGCC 4750 TAAAGTTGAA GGTGGATTTC CGTCCGATTG GTCTGTATGC AGGTGTTGTG 4800 GTGGCCCCCG GCCTTGGCGC GCTTCCTGAT GTCGTGCGCT TCGCCGGTCG 4850 GCTTACTGAG AAGAATTGGG GCCCTGGCCC CGAGCGGGCG GAGCAGCTCC 4900 GCCTCGCTGT GAGTGATTTT CTCCGCAAGC TCACGAATGT AGCTCAGATG 4950 TGTGTGGATG TTGTCTCTCG TGTTTATGGG GTTTCCCCTG GGCTCGTTCA 5000 TAACCTGATT GGCATGCTAC AGGCTGTTGC TGATGGCAAG GCTCATTTCA 5050 CTGAGTCAGT GAAGCCAGTG CTTGACCTGA CAAATTCAAT TCTGTGTCGG 5100 GTGGAATGAA TAACATGTCT TTTGCTGCGC CCATGGGTTC GCGACCATGC 5150 GCCCTCGGCC TATTTTGCTG TTGCTCCTCA TGTTTCTGCC TATGCTGCCC 5200 GCGCCACCGC CCGGTCAGCC GTCTGGCCGC CGTCGTGGGC GGCGCAGCGG 5250 CGGTTCCGGC GGTGGTTTCT GGGGTGACCG GGTTGATTCT CAGCCCTTCG 5300 CAATCCCCTA TATTCATCCA ACCAACCCCT TCGCCCCCGA TGTCACCGCT 5350 GCGGCCGGGG CTGGACCTCG TGTTCGCCAA CCCGCCCGAC CACTCGGCTC 5400 CGCTTGGCGT GACCAGGCCC AGCGCCCCGC CGCTGCCTCA CGTCGTAGAC 5450 CTACCACAGC TGGGGCCGCG CCGCTAACCG CGGTCGCTCC GGCCCATGAC 5500 ACCCCGCCAG TGCCTGATGT TGACTCCCGC GGCGCCATCC TGCGCCGGCA 5550 GTATAACCTA TCAACATCTC CCCTCACCTC TTCCGTGGCC ACCGGCACAA 5600 ATTTGGTTCT TTACGCCGCT CCTCTTAGCC CGCTTCTACC CCTCCAGGAC 5650 GGCACCAATA CTCATATAAT GGCTACAGAA GCTTCTAATT ATGCCCAGTA 5700 CCGGGTTGCT CGTGCCACAA TTCGCTACCG CCCGCTGGTC CCCAACGCTG 5750 TTGGTGGCTA CGCTATCTCC ATTTCGTTCT GGCCACAGAC CACCACCACC 5800 CCGACGTCCG TTGACATGAA TTCAATAACC TCGACGGATG TCCGTATTTT 5850 AGTCCAGCCC GGCATAGCCT CCGAGCTTGT TATTCCAAGT GAGCGCCTAC 5900 ACTATCGCAA CCAAGGTTGG CGCTCTGTTG AGACCTCCGG GGTGGCGGAG 5950 GAGGAGGCCA CCTCTGGTCT TGTCATGCTC TGCATACATG GCTCACCTGT 6000 AAATTCTTAT ACTAATACAC CCTATACCGG TGCCCTCGGG CTGTTGGACT 6050 TTGCCCTCGA ACTTGAGTTC CGCAACCTCA CCCCCGGTAA TACCAATACG 6100 CGGGTCTCGC GTTACTCCAG CACTGCCCGT CACCGCCTTC GTCGCGGTGC 6150 AGATGGGACT GCCGAGCTCA CCACCACGGC TGCTACTCGC TTCATGAAGG 6200 ACCTCTATTT TACTAGTACT AATGGTGTTG GTGAGATCGG CCGCGGGATA 6250 GCGCTTACCC TGTTTAACCT TGCTGACACC CTGCTTGGCG GTCTACCGAC 6300 AGAATTGATT TCGTCGGCTG GTGGCCAGCT GTTCTACTCT CGCCCCGTCG 6350 TCTCAGCCAA TGGCGAGCCG ACTGTTAAGC TGTATACATC TGTGGAGAAT 6400 GCTCAGCAGG ATAAGGGTAT TGCAATCCCG CATGACATCG ACCTCGGGGA 6450 ATCCCGTGTA GTTATTCAGG ATTATGACAA CCAACATGAG CAGGACCGAC 6500 CGACACCTTC CCCAGCCCCA TCGCGTCCTT TTTCTGTCCT CCGAGCTAAC 6550 GATGTGCTTT GGCTTTCTCT CACCGCTGCC GAGTATGACC AGTCCACTTA 6600 CGGCTCTTCG ACCGGCCCAG TCTATGTCTC TGACTCTGTG ACCTTGGTTA 6650 ATGTTGCGAC CGGCGCGCAG GCCGTTGCCC GGTCACTCGA CTGGACCAAG 6700 GTCACACTTG ATGGTCGCCC CCTTTCCACC ATCCAGCAGT ATTCAAAGAC 6750 CTTCTTTGTC CTGCCGCTCC GCGGTAAGCT CTCCTTTTGG GAGGCAGGAA 6800 CTACTAAAGC CGGGTACCCT TATAATTATA ACACCACTGC TAGTGACCAA 6850 CTGCTCGTTG AGAATGCCGC TGGGCATCGG GTTGCTATTT CCACCTACAC 6900 TACTAGCCTG GGTGCTGGCC CCGTCTCTAT TTCCGCGGTT GCTGTTTTAG 6950 CCCCCCACTC TGTGCTAGCA TTGCTTGAGG ATACCATGGA CTACCCTGCC 7000 CGCGCCCATA CTTTCGATGA CTTCTGCCCG GAGTGCCGCC CCCTTGGCCT 7050 CCAGGGTTGT GCTTTTCAGT CTACTGTCGC TGAGCTTCAG CGCCTTAAGA 7100 TGAAGGTGGG TAAAACTCGG GAGTTATAGT TTATTTGCTT GTGCCCCCCT 7150 TCTTTCTGTT GCTTATTT 7168 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: ACATTTGAAT TCACAGACAT TGTGC 25 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: ACACAGATCT GAGCTACATT CGTGAG 26 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANPEDNESS: single (P) TOPOLOGY: linear (xi) SEQUENCE PESCRIPTION: SEQ ID NO:7: AAAGGGATCC ATGGTGTTTG AGAATG 26 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANPEPNESS: single (P) TOPOLOGY: linear (Xi) SEQUENCE PESCRIPTION: SEQ IP NO:8: ACTCACTGCA GAGCACTATC GAATC 25 (2) INFORMATION FOR SEQ IP NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANPEPNESS: single (P) TOPOLOGY: linear ( i) SEQUENCE PESCRIPTION: SEQ IP NO:9: CGGTAAACTG GTACTGCACA AC 22 (2) INFORMATION FOR SEQ IP NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANPEPNESS: single (P) TOPOLOGY: linear (xi) SEQUENCE PESCRIPTION: SEQ ID NO: 10: AAGTCCCGCT CTATTACCCA AG 22 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE PESCRIPTION: SEQ IP NO:11: ACCCACGGGT GTTGGTTTTT G 21 (2) INFORMATION FOR SEQ IP NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANPEPNESS: single (P) TOPOLOGY: linear ( i) SEQUENCE PESCRIPTION: SEQ IP NO: 12: TTCTTGGGGC AGGTAGAGAA G 21 (2) INFORMATION FOR SEQ IP NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANPEPNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 13: TTATTGAATT CATGTCAACG GACGTC 26 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: AATAATTCAT GCCGTCGCTC C 21 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: AAGCTCAGGA AGGTACAACT C 21 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: AAATCGATGG CTGGGATCTG ATTC 24 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: GAGGCATTGT AGAGCTTTGT G 21 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: GATGTTGCAC GGACAGCAAA TC 22 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: ATCTCCGATG CAATCGTTAA TAAC 24 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: TAATCCATTC TGTGGCGAGA G 21 (2) INFORMATION FOR SEQ IP NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANPEPNESS: single (P) TOPOLOGY: linear (xi) SEQUENCE PESCRIPTION: SEQ ID NO:21: AAGTGTGACC TTGGTCCAGT C 21 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: TTGCTCGTGC CACAATTCGC TAC 23 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: CATTTCACTG AGTCAGTGAA G 21 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: TAATTATAAC ACCACTGCTA G 21 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: GATTGCAATA CCCTTATCCT G 21 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: ATTAAACCTG TATAGGGCAG AAC 23 (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: AAGTTCGATA GCCAGATTTG C 21 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: TCATGTTGGT TGTCATAATC C 21 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: GATGACGCAC TTCTCAGTGT G 21 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE PESCRIPTION: SEQ ID NO:30: AGAACAACGA ACGGAGAAC 19 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: AGATCCCAGC CATCGACTTT G 21 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: TAGTAGTGTA GGTGGAAATA G 21 (2) INFORMATION FOR SEQ IP NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANPEPNESS: single (P) TOPOLOGY: linear (xi) SEQUENCE PESCRIPTION: SEQ ID NO:33: GTGTGGTTAT TCAGGATTAT G 21 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: ACTCTGTGAC CTTGGTTAAT G 21 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: AACTCAAGTT CGAGGGCAAA G 21 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE PESCRIPTION: SEQ IP NO: 36: CGCTTACCCT GTTTAACCTT G 21 (2) INFORMATION FOR SEQ IP NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANPEPNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: ATCCCCTATA TTCATCCAAC CAAC 24 (2) INFORMATION FOR SEQ IP NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (P) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: CTCCTCATGT TTCTGCCTAT G 21 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: GCCAGAACGA AATGGAGATA GC 22 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO:40: CTCAGACATA AAACCTAAGT C 21 (2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: TGCCCTATAC AGGTTTAATC G 21 (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE PESCRIPTION: SEQ IP NO:42: ACCGGCATAT ACCAGGTGC 19 (2) INFORMATION FOR SEQ IP NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: ACATGGCTCA CTCGTAAATT C 21 (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANPEPNESS: single (P) TOPOLOGY: linear (xi) SEQUENCE PESCRIPTION: SEQ ID NO:44: AACATTAGAC GCGTTAACGA G 21 (2) INFORMATION FOR SEQ ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: CTCTTTTGAT GCCAGTCAGA G 21 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: ACCTACCCGG ATGGCTCTAA GG 22 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:47: TATGGGAATT CGTGCCGTCC TGAAG 25 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: AGTGGGAGCA GTATACCAGC G 21 (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: CTGCTATTGA GCAGGCTGCT C 21 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50: GGGCCATTAG TCTCTAAAAC C 21 (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: GAGGTTTTCT GGAATCATC 19 (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 15 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: GCATAGGTGA GACTG 15 (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53: AGTTACAGCC AGAAAACC 18 (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO:54: CCATGGATCC TCGGCCTATT TTGCTGTTGC TCC 33 (2) INFORMATION FOR SEQ ID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: AGGCAGACCA CATATGTG 18 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56: GGTGCACTCC TGACCAAGCC 20 (2) INFORMATION FOR SEQ ID NO: 57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: ATTGGCTGCC ACTTTGTTC 19 (2) INFORMATION FOR SEQ ID NO: 58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: ACCCTCATAC GTCACCACAA C 21 (2) INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:59: GCGGTGGACC ACATTAGGAT TATC 24 (2) INFORMATION FOR SEQ ID NO: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60: CATGATATGT CACCATCTG 19 (2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO:61: GTCATCCATA ACGAGCTGG 19 (2) INFORMATION FOR SEQ ID NO: 62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO:62: AGCGGAATTC GAGGGGCGGC ATAAAGAACC AGG 33 (2) INFORMATION FOR SEQ ID NO: 63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:63: GCGCTGAATT CGGATCACAA GCTCAGAGGC TATGCC 36 (2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: .single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:64: GTATAACGGA TCCACATCTC CCCTTACCTC 30 (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65: TAACCTGGAT CCTTATGCCG CCCCTCTTAG 30 (2) INFORMATION FOR SEQ ID NO: 66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66: AAATTGGATC CTGTGTCGGG TGGAATGAAT AACATGTC 38 (2) INFORMATION FOR SEQ ID NO: 67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 37 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: ATCGGCAGAT CTGATAGAGC GGGGACTTGC CGGATCC 37 (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO: 68: TACCCTGCCC GCGCCCATAC TTTTGATG 28 (2) INFORMATION FOR SEQ ID NO: 69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:69: GGCTGAGATC TGGTTCGGGT CGCCAAGAAG GTG 33 (2) INFORMATION FOR SEQ ID NO: 70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO:70: TACAGATCTA TACAACTTAA CAGTCGG 27 (2) INFORMATION FOR SEQ ID NO: 71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71: . GCGGCAGATC TCACCGACAC CATTAGTAC 29 (2) INFORMATION FOR SEQ ID NO: 72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:72: CCGTCGGATC CCAGGGGCTG CTGTCCTG 28 (2) INFORMATION FOR SEQ ID NO: 73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO:73: AAAGGAATTC AAGACCAGAG GTAGCCTCCT C 31 (2) INFORMATION FOR SEQ ID NO: 74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:74: GTTGATATGA ATTCAATAAC CTCGACGG 28 (2) INFORMATION FOR SEQ ID NO: 75: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75: TTTGGATCCT CAGGGAGCGC GGAACGCAGA AATGAG 36 (2) INFORMATION FOR SEQ ID NO: 76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76: TCACTCGTGA ATTCCTATAC TAATAC 26 (2) INFORMATION FOR SEQ ID NO: 77: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:77: TTTGGATCCT CAGGGAGCGC GGAACGCAGA AATG 34 (2) INFORMATION FOR SEQ ID NO: 78: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:78: TGATAGAGCG GGACTTGCCG GATCC 25 (2) INFORMATION FOR SEQ ID NO: 79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: TTGCATTAGG TTAATGAGGA TCTC 24 (2) INFORMATION FOR SEQ ID NO: 80: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:80: ACCTGCTTCC TTCAGCCTGC AGAAG 25 (2) INFORMATION FOR SEQ ID NO: 81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:81: GCGGTGGATC CGCTCCCAGG CGTCAAAAC 29 (2) INFORMATION FOR SEQ ID NO: 82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:82: GGGCGGATCG AATTCGAGAC CCTTCTTGG 29 (2) INFORMATION FOR SEQ ID NO: 83: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83: AGGATGGATC CATAAGTTAC CGATCAG 27 (2) INFORMATION FOR SEQ ID NO: 84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANPEPNESS: single (P) TOPOLOGY: linear (xi) SEQUENCE PESCRIPTION: SEQ IP NO:84: GGCTGGAATT CCTCTGAGGA CGCCCTCAC 29 (2) INFORMATION FOR SEQ IP NO: 85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANPEDNESS: single (P) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:85: GCCGAAGATC TATCGGACAT AGACCTC 27 (2) INFORMATION FOR SEQ ID NO: 86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO:86: CAGACGACGG ATCCCCTTGG ATATAGCCTG 30 (2) INFORMATION FOR SEQ ID NO: 87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 40 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear ( i) SEQUENCE DESCRIPTION: SEQ ID NO:87: GGCCGAATTC AGGCAGACCA CATATGTGGT CGATGCCATG 40 (2) INFORMATION FOR SEQ ID NO: 88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE PESCRIPTION: SEQ ID NO: 88: GCAGGTGTGC CTGGATCCGG CAAGT 25 (2) INFORMATION FOR SEQ ID NO: 89: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:89: GTTAGAATTC CGGCCCAGCT GTGGTAGGTC 30 (2) INFORMATION FOR SEQ ID NO: 90: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:90: CCGTCCGATT GGTCTGTATG CAGG 24 (2) INFORMATION FOR SEQ ID NO: 91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91: TACCAGTTTA CTGCAGGTGT GC 22 (2) INFORMATION FOR SEQ ID NO: 92: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92: CAAGCCGATG TGGACGTTGT CG 22 (2) INFORMATION FOR SEQ ID NO: 93: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93: GGCGCTGGGC CTGGTCACGC CAAG 24 (2) INFORMATION FOR SEQ ID NO: 94: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:94: GCAGAAACTA GTGTTGACCC AG 22 (2) INFORMATION FOR SEQ ID NO: 95: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:95: TAGGTCTACG ACGTGAGGCA AC 22 (2) INFORMATION FOR SEQ ID NO: 96: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:96: TACAATCTTT CAGGAAGAAG G 21 (2) INFORMATION FOR SEQ ID NO: 97: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:97: CCCACACTCC TCCATAATAG C 21 (2) INFORMATION FOR SEQ ID NO: 98: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:98: GATAGTGCTT TGCAGTGAGT ACCG 24

Claims: CLAIMS 1. An isolated and purified virus comprising hepatitis E strain SAR-55. 2. The cDNA of hepatitis E wherein the cDNA has a cDNA sequence according to SEQ ID No. 4. 3. A synthetic DNA sequence comprising a sequence capable of directing host organism synthesis of at least one complete open reading frame protein, said protein having substantial homology to a protein from HEV, or a variant of said protein. 4. A cDNA sequence of Claim 3, wherein said cDNA encodes a protein comprising the amino acid sequence of SEQ ID NO. 2, or a variant thereof. 5. A recombinant protein derived from the cDNA sequence of claim 2. 6 « The recombinant protein of claim 5 wherein the protein is encoded by cDNA sequence comprising a complete ORF. 7. A protein comprising the amino acid sequence of SEQ ID NO. 2 or substantially homologous sequence thereof. 8. A method of producing a recombinant HEV protein, comprising: (a) cloning a cDNA sequence of HEV; (b) inserting the cDNA sequence into an expres¬ sion vector; (c) transferring the expression vector into a host organism; (d) culturing the host organism under conditions appropriate for amplification of the vector and ° expression of the protein; and (e) harvesting the protein. 9. The method of claim 8, wherein the expression vector is a eukaryotic expression vector. 10. The method of claim 8, wherein the expression vector is a baculovirus vector. 11. The method of claim 8, wherein the host organism is a eukaryotic cell. 12. The method of claim 11, wherein the eukaryotic cell is an insect cell. 13. The method of claim 8, wherein the cDNA sequence encodes a complete open-reading frame. 14. The method of claim 13, wherein the cDNA sequence encodes complete open-reading frame 2. 15. A recombinant expression vector comprising a cDNA sequence encoding a complete open-reading frame of HEV. 16. A recombinant expression vector comprising: a cDNA sequence according to SEQ ID 4. 17. The recombinant expression vector of claim 15, wherein the cDNA sequence encodes a complete open-reading frame 2. 18. The recombinant expression vector of claim 15, wherein the vector is p63-2. 19. A host organism transformed or transfected with a recombinant expression vector according to claim 15. 20. A method for the recombinant DNA synthesis of at least one complete open reading frame protein of HEV comprising: (a) culturing a transformed or transfected host organism containing a DNA sequence capable of directing the host organism to produce an open reading frame protein under conditions such that the protein is produced, said protein exhibiting substantial homology to a protein comprising the amino acid sequence of SEQ ID NO.: 2; and (b) harvesting the protein. 21. A method of detecting antibodies to Hepatitis E in a biological sample suspected of containing said antibodies comprising: (a) contacting the sample with the recombinant HEV protein of claim 7 to form an immune complex with the antibodies; and (b) detecting the presence of the immune complex. 22. The method of claim 21, wherein the biological sample is selected from the group consisting of whole blood, plasma, serum, cerebrospinal fluid, tissue, urine and pleural fluid. 23. The method of claim 21, wherein IgM or IgG anti¬ body is detected. 24. The method of claim 21, wherein the recombinant HEV protein is bound to a solid support. 25. The method of claim 21, wherein the immune complex is detected using a labeled antibody. 26. A kit for use in a method of claim 21 comprising: ° a recombinant HEV protein comprising an amino acid sequence of SEQ ID No. 2 or a substantially homologous sequence thereof. 27. The kit of claim 26 further comprising a labeled secondary antibody. 28. A pharmaceutical composition comprising the recombinant protein of claim 5 or 6 and a suitable excipient, diluent or carrier. 29. A method of preventing hepatitis E, comprising administering the pharmaceutical composition of claim 28 to a mammal in an effective amount to stimulate the production of protective antibody. 30. A vaccine for immunizing a mammal against hepatitis E infection, comprising a recombinant protein according to claim 6 or 7 in a pharmacologically acceptable carrier. 31. The vaccine of claim 30, wherein the recombinant protein is derived from a complete open reading frame 2.

Inventors: EMERSON SUZANNE U, PURCELL ROBERT H, TSAREV SERGEI A, EMERSON, SUZANNE, U., PURCELL, ROBERT, H., TSAREV, SERGEI, A.
Applicants: US HEALTH, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS
Application year: 1993
Main classification: C12N15
IPC codes: A61K38, A61K39, A61P31, A61P43, C07K14, C12N1, C12N5, C12N7, C12N15, C12P21, G01N33